Document:

Exhibit

Exhibit 10.15
CONFIDENTIAL TREATMENT REQUESTED

THE GENERAL HOSPITAL CORPORATION 

AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT
MGH Agreement No: A209968  
MGH Case Nos: 02595 and 21131
This Exclusive License Agreement (this “Agreement”) is made as of the 6th day of November, 2017 (the “Restated Effective Date”), by and between OvaScience, Inc., a Delaware corporation, having a principal place of business at 9 Fourth Avenue, Waltham, MA 02451 (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
RECITALS
Hospital, as a center for patient care, research and education, is the owner of certain Patent Rights (defined below) and desires to grant a license of those Patent Rights to Company in order to benefit the public by disseminating the results of its research via the commercial development, manufacture, distribution and use of Products and Processes (defined below). 
Hospital has entered into a Joint Invention Administration agreement (the “JIA”) with the President and Fellows of Harvard College (“Harvard”) wherein Hospital is the exclusive agent to grant licenses to the certain patent rights in the field of ex-vivo human fertility.
Company and Hospital entered into the Exclusive License Agreement dated June 27, 2011 (the “Original Agreement Effective Date”), as amended by amendments dated September 7th 2011, July 30th 2013, September 9th 2013, November 14th 2013, and December 18th 2013 (as so amended, the “Original Agreement”).
Company and Hospital entered into a Binding Term Sheet (the “Binding Term Sheet”) dated as of August 29, 2016, which is attached hereto as Appendix A.
Company and Hospital desire to amend and restate in all respects the Original Agreement and replace and supersede the terms of the Original Agreement with the terms set forth in the Binding Term Sheet, as provided in this Agreement, as of the Restated Effective Date.
Company has the capability to commercially develop, manufacture, distribute and use Products and Processes for public use and benefit and desires to license such Patent Rights.
For good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

Page 1 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

1.  CERTAIN DEFINITIONS
As used in this Agreement, the following terms shall have the following meanings, unless the context requires otherwise.
1.1    “Affiliate” with respect to either Party shall mean any corporation or other legal entity other than that Party, in whatever country organized, that controls, is controlled by or is under common control with that Party.  The term “control” shall mean (a) in the case of Company, direct or indirect ownership of fifty percent (50%) or more of the voting securities having the right to elect directors, or the power, direct or indirect, to cause the direction of management and policies, whether by contract or otherwise and (b) in the case of Hospital, the power, direct or indirect, to elect or appoint fifty percent (50%) or more of the directors or trustees, or to cause direction of management and policies, whether through the ownership of voting securities, by contract or otherwise.
1.2    “Claim” shall mean any pending or issued claim of any Patent Right that has not been abandoned or permanently revoked, nor held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is unappealable or unappealed in the time allowed for appeal.
1.3    “Clinical End User” shall mean those laboratories, clinics and medical practices that purchase and/or use Products and/or Processes pursuant to agreements with Company or any of its Affiliates or Sublicensees.
1.4    “Clinical Proof of Concept” shall mean the completion of a clinical study conducted by or on behalf of Company or any of its Affiliates or Sublicensees of a Product or Process using the Hospital Patent Rights, consisting of a minimum of [***] women patients, in which the average pregnancy rate (as measured by fetal heart beat) of all women in such study is at least [***] percent ([***]%) above the average pregnancy rate via fresh embryo transfer in the most recent National SART Clinic Summary Report for the age group adjusted average, as a result of the use of such Product or Process.
1.5    “Combination Product or Process” shall mean a product or process that uses a functionally active component (for clarity, functionally active components exclude routine components, including without limitation common buffers and standard cell culture media) or service offering or process not licensed by Hospital to Company hereunder (“Other Components”) to form a product or process that is a combination of a Product and/or Process and Other Component(s).  For example, and without limiting the generality of this definition, a product or process in which (i) egg precursor cells are matured into an oocyte by a process that would qualify as a Process, and (ii) the resulting oocytes are subjected to a treatment or a product which would not qualify as a Process or Product, respectively, would be a Combination Product or Process.
1.6    “Commercially Reasonable Efforts” shall mean, with respect to the conduct by Company the level of effort and resources that is typically used by a for-profit company of a similar size and profile as Company in the healthcare industry, for the research, development, and/or 

Page 2 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

commercialization of a similarly situated product at a similar stage of development and/or commercialization as such a Product or Process, taking into account all scientific, commercial and other relevant factors, including (a) considerations of strategy, (b) the presence or absence of intellectual property protection, and (c) any regulatory requirements or concerns.    
1.7    “Distributor” shall mean any third party entity to which Company or any of its Affiliates or Sublicensees has granted, express or implied, the right to distribute any Product or Process pursuant to Section 2.1(b)(ii).
1.8    “Excusable Delay” shall mean the occurrence of (a) an event of Force Majeure; (b) any event, condition or circumstance that is not attributable to any breach of this Agreement by Company (including an event, condition or circumstance related to the performance or manufacture or supply of a Product or Process or any material component thereof)  that materially affects the conduct of clinical studies, (c) any potential or actual regulatory action by any regulatory authority with respect to a Product or Process (or any material component thereof) that materially affects Company’s performance of any of its obligations under this Agreement, or (d) any event, condition or circumstance that is materially adverse to the Patent Rights licensed hereunder, including any absence of, any challenge to, or any enforceability issue regarding any issued Patent Rights, and claims of infringement by a third party of its patent rights. 
1.9    “First Commercial Sale” shall mean the initial Sale anywhere of a Product or Process that is either (a) to any party that is not part of a clinical study sponsored by Company or any of its Affiliates or Sublicensees, or (b) not used or intended to be used for a patient enrolled in a clinical study sponsored by Company or any of its Affiliates or Sublicensees; and provided, that, Company or any of its Affiliates or Sublicensees has either (i) received all approvals from the FDA or other equivalent relevant regulatory authority in that country necessary for the commercial marketing of such Product or Process or (ii) completed enrollment and treatment of at least [***] women in a Clinical Proof of Concept study.  
1.10    “Hospital Patent Rights” shall mean, inclusively, (a) the following patent applications: [***], filed on [***], [***], filed on [***], [***], filed on [***], [***], filed on [***], [***], filed on [***], [***], filed on [***], [***], [***], filed on [***], filed on [***], and [***], filed on [***]; and (b) the equivalent of any of the applications described in subsection (a), including any divisional, continuation (including claims of continuations-in-part only to the extent entirely supported by the specification of the application on which such continuations-in-part are based), foreign counterpart patent application, Letters Patent and/or the equivalent thereof issuing thereon, and/or reissue, reexamination or extension thereof, or supplementary protection certificate or patents of addition relating thereto.

1.11    “License Field” shall mean any and all uses.

1.12    “License Territory” shall mean worldwide.
1.13    “Limited Field” shall mean ex-vivo human female fertility treatments and shall specifically exclude (a) treatments of menopause associated symptoms or diseases other than treatments of infertility; (b) treatments to delay menopause or menopause associated symptoms 

Page 3 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

or diseases other than treatments of infertility; (c) diagnostics; and (d) research tools, or any other field not specifically set forth herein. For purposes of this definition, ex vivo human female fertility treatments shall be deemed to include the treatment of sperm in relation to in vitro fertilization treatments.
1.14    “Media Patent Rights” shall mean, inclusively, (a) the following patent applications: U.S. Provisional Patent Application No. [***], filed on [***], U.S. Provisional Patent Application No. [***], filed on [***], PCT Application No. [***], filed on [***]; and (b) the equivalent of any of the applications described in subsection (a), including any divisional, continuation (including claims of continuations-in-part only to the extent entirely supported by the specification of the application on which such continuations-in-part are based), foreign counterpart patent application, Letters Patent and/or the equivalent thereof issuing thereon, and/or reissue, reexamination or extension thereof, or supplementary protection certificate or patents of addition relating thereto. 
1.15    “Net Sales” shall be calculated as set forth in this Section 1.15.
		
	(a)
	 Subject to the conditions set forth below, “Net Sales” shall mean:

		
	(i)
	the gross amount billed or invoiced by Company and its Affiliates and Sublicensees for or on account of Sales of Products and/or Processes; provided that, with respect to the Sale and/or use of Products and/or Processes by Clinical End Users (in their capacities as Clinical End Users), the amounts paid by Clinical End Users to Company, its Affiliates and Sublicensees shall be considered gross amounts billed or invoiced for purposes of calculating Net Sales and the amounts billed or invoiced by Clinical End Users for Sales to their consumer shall be excluded from the calculation of Net Sales;

		
	(ii)
	less the following:

		
	(A)
	to the extent paid or credited by Company and its Affiliates and Sublicensees the amounts repaid or credited by reason of rejection or return of applicable Products or Processes;

		
	(B)
	reasonable and customary trade, quantity or cash rebates or discounts to the extent allowed and taken;

		
	(C)
	amounts for outbound transportation, insurance, handling and shipping, but only to the extent separately invoiced or identified in a manner that clearly specifies the charges applicable to the applicable Products or Processes; 

		
	(D)
	taxes, customs duties and other governmental charges levied on or measured by Sales of Products or Processes, to the extent separately invoiced, whether paid by or on behalf of Company so 

Page 4 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

long as Company’s price is reduced thereby, but not franchise or income taxes of any kind whatsoever;
		
	(E)
	the gross amount received by Company and its Affiliates and Sublicensees for or on account of Sales of Products and Processes to Hospital and/or Hospital’s Affiliates; and

		
	(F)
	the gross amounts billed or invoiced by Company and its Affiliates and Sublicensees in prior periods for or on account of Sales of Products and Processes that are not received within [***)] months of billing or invoicing and are charged off or written off as uncollectable, such amounts not to exceed [***] percent ([***]%) of gross amounts billed or invoiced.

		
	(b)
	Specifically excluded from the definition of “Net Sales” are amounts attributable to any Sale of any Product or Process between or among Company and any Company Affiliate and/or Sublicensee, unless the transferee is the end purchaser, user or consumer of such Product or Process.

		
	(c)
	No deductions shall be made for any commissions paid to any individuals or for any costs or expenses of collections.

		
	(d)
	Net Sales shall be deemed to have occurred and the applicable Product or Process “Sold” on the date billed or invoiced by Company and its Affiliates and Sublicensees.

		
	(e)
	If any Product or Process is Sold for non-cash consideration, Net Sales shall be calculated based on the average cash amount charged to independent third parties for the Product or Process in the same country during the same Reporting Period or, in the absence of such transactions, on the fair market value of the Product or Process.  In addition, Company shall not grant discounts on Sales of Products or Processes in exchange for any consideration other than the Sale price of such Products or Processes without the prior written consent of Hospital.

		
	(f)
	Notwithstanding the foregoing, if Company or any of its Affiliates (or Sublicensees for which Net Sales are not established pursuant to clause (a)(i) above, if any) use and/or sell Products and/or Processes as a Clinical End User, such use and/or sale shall be deemed a Sale and Net Sales based on such Sale shall be deemed to be an amount determined as follows:

		
	(i)
	the average Net Sales amount resulting from equivalent uses and/or Sales of Products and/or Processes by independent third party Clinical End Users in the same country as such Sale during the same Reporting Period; or

Page 5 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(ii)
	in the absence of transactions referenced in clause (f)(i) above, the Parties shall first discuss an alternative Net Sales amount to use until such time, if ever, there are independent third party Clinical End User transactions that can be used to calculate imputed Net Sales.  Absent agreement on an alternative Net Sales amount, a royalty in the amount of [***] dollars ($[***]) shall be payable (during the royalty term specified in Section 10.1) on each use and/or Sale by Company or its Affiliates (or Sublicensees for which Net Sales are not established pursuant to clause (a)(i) above, if any) in lieu of the royalty amount calculated in Section 4.5(a) until such time, if ever, as there are independent third party Clinical End User transactions that can be used to calculate Net Sales in accordance clause (f)(i) above.

		
	(iii)
	the Net Sales or royalty determined in accordance with the foregoing clauses (f)(i) and (f)(ii) shall be in lieu of any other calculation of Net Sales or royalties, as applicable, based on such use and/or Sale.

		
	(g)
	For purposes of determining Net Sales attributable to the Sale of a Combination Product or Process, such Net Sales shall be calculated as follows:

		
	(i)
	the Net Sales of the Combination Product or Process would be multiplied by the fraction A/A+B, where A is the average selling price, during the Reporting Period in question, of the Product or Process incorporated within the Combination Product or Process sold separately in the country in which the Sale of the Combination Product or Process is made, and B is the average selling price, during the Reporting Period in question, of the Other Components sold separately;  however, Net Sales shall be calculated as described in part (ii) below if (A) either one or both of A and B cannot be determined (e.g., A and B are not sold separately) or (B) part (ii) below is more appropriate under the circumstances (e.g., generally fits the example provided in part (ii) below);

		
	(ii)
	the Net Sales of the Combination Product or Process would be multiplied by the fraction C/D where D is the average selling price of the Combination Product sold in a given market and C is the average selling price of the isolated royalty-bearing Product or Process sold in that market (By way of example, if Company sells an EggPC-derived egg or embryo in a market such as animal husbandry and the embryo does not utilize the proprietary technology of any third party, the egg/standard embryo would be deemed to be the royalty-bearing Product or Process for purposes of the above formula and the ultimate cow generated would deemed to be the Combination Product for purposes of the above formula).

If the Other Components, and the underlying incorporated Products or Processes, in the Combination Product or Process are not sold separately, then for the purposes of determining royalties payable hereunder, the Parties shall negotiate in 

Page 6 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

good faith to determine Net Sales attributable to such Combination Product or Process accordingly.  
1.16     “Patent Rights” shall mean, collectively, the Hospital Patent Rights and the Media Patent Rights. 
1.17    “Process” shall mean any process, method or service the use or performance of which, in whole or in part:
		
	(a)
	absent the license granted hereunder would infringe, or is covered by, one or more Claims of Patent Rights; or

		
	(a)
	employs, is based upon or is derived from Technological Information.

1.18    “Product” shall mean any article, device or composition, the manufacture, use, or sale of which, in whole or in part:
		
	(a)
	absent the license granted hereunder would infringe, or is covered by, one or more Claims of Patent Rights; or

		
	(b)
	employs, is based upon or is derived from Technological Information.

1.19    “Reporting Period” shall mean each three month period ending March 31, June 30, September 30 and December 31.
1.20    “Sell” (and “Sale” and “Sold” as the case may be) shall mean to sell or have sold, to lease or have leased, to import or have imported or otherwise to transfer or have transferred a Product or Process for valuable consideration (in the form of cash or otherwise), and further in the case of a Process to use or perform such Process for the benefit of a third party for valuable consideration (in the form of cash or otherwise).
1.21    “Sublicensee” shall mean any sublicensee of rights granted in accordance with Section 2.1(a)(ii).  For purpose of this Agreement, a Distributor of a Product or Process shall not be included in the definition of Sublicensee unless such Distributor (a) is granted any right to make, have made, use or have used Products or Processes in accordance with Section 2.1(a)(ii), or (b) has agreed to pay to Company or its Affiliate(s) royalties on such Distributor’s sales of Products or Processes, in which case such Distributor shall be a Sublicensee for all purposes of this Agreement.
1.22    “Sublicense Income” shall mean consideration in any form received by Company and/or Company’s Affiliate(s) in connection with or otherwise attributable to a grant of a sublicense or any other right, license, privilege or immunity (regardless of whether such grantee is a “Sublicensee” as defined in this Agreement) to make, have made, use, have used, Sell or have Sold Products or Processes, including:  (i) any license signing or maintenance fee; (ii) royalties (other than Net Sales paid pursuant to this Agreement); (iii) any unearned portion of any minimum royalty payment;(iv) any distribution or joint marketing fee; (v) any research and development funding exceeding the reasonable cost (including reasonable allocations of 

Page 7 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

overhead) of performing such research and development; (vi) any funding for training in the use of Products and Processes exceeding reasonable cost-based funding (including without limitation travel costs and costs of training materials); and (vii) any consideration received for an equity interest in, extension of credit to (including but not limited to through convertible debt) or other investment in Company or Company’s Affiliates to the extent such consideration exceeds the fair market value of the equity or other interest received as determined by agreement of the Parties or by an independent appraiser mutually agreeable to the Parties. For the avoidance of doubt, consideration included within Net Sales shall not be deemed Sublicense Income. 
1.23    “Technological Information” shall mean research data, designs, formulae, process information and other information pertaining to the invention(s) claimed in the Patent Rights which is created by Dr. Tilly and owned by Hospital and is not confidential information of or otherwise obligated to any third party and which Dr. Tilly knows as of the Original Agreement Effective Date and reasonably believes is necessary in order for Company to utilize the licenses granted hereunder, as further described in Appendix B.  Company agrees to treat all Technological Information in accordance with the provisions of Appendix C.
    
2.      LICENSE
2.1    Grant of License.
		
	(a)
	Subject to the terms of this Agreement and Hospital’s and Harvard’s respective retained rights in Patent Rights (as outlined in Section 2.3), Hospital hereby grants to Company:

		
	(i)
	an exclusive, royalty-bearing license under Hospital’s rights in Hospital Patent Rights to make, have made, use, have used, Sell and have Sold Products and Processes in the License Field in the License Territory; 

		
	(ii)
	an exclusive, royalty-bearing license under Hospital’s and Harvard’s respective rights in Media Patent Rights to make, have made, use, have used, Sell and have Sold Products and Processes in the Limited Field in the License Territory;

		
	(iii)
	the right to grant sublicenses under the rights granted in Section 2.1(a)(i), (ii) to Sublicensees, provided, that, in each case Company shall be responsible for the performance of any obligations of Sublicensees relevant to this Agreement as if such performance were carried out by Company itself, including, without limitation, the payment of any royalties or other payments provided for hereunder, regardless of whether the terms of any sublicense provide for such amounts to be paid by the Sublicensee directly to Hospital; and

Page 8 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(i)
	the nonexclusive right to use Technological Information disclosed by Hospital to Company hereunder in accordance with this Agreement.

		
	(b)
	The licenses granted in Section 2.1(a)(i) and (ii) above include:

		
	(i)
	the right to grant to Clinical End Users and to final purchasers, users or consumers of Products or Processes the right to use such purchased Products or Processes within the scope of Hospital Patent Rights within the License Field, and/or within the scope of Media Patent Rights within the Limited Field, in all cases in the License Territory; and

		
	(ii)
	the right to grant a Distributor the right to Sell (but not to make, have made, use or have used) such Products and/or Processes for or on behalf of Company, its Affiliates and Sublicensees in a manner consistent with this Agreement.

		
	(c)
	The foregoing license grants shall include the right of Company to grant some or all of its rights under this Agreement to any Affiliate of Company, provided that (i) such Affiliate has been expressly granted such rights in writing by Company (such agreement an “Affiliate Agreement”), (ii) such Affiliate Agreement shall contain the same obligations as those of Company and be subject to the same terms and conditions hereunder, and (iii) Company shall be responsible for the performance of all such obligations and for compliance with all such terms and conditions by such Affiliate.  Company shall (i) provide prompt written notice upon execution of each Affiliate Agreement and (ii) provide to Hospital a fully signed, non-redacted copy of each Affiliate Agreement that assumes the aforesaid obligations, including all exhibits, attachments and related documents and any amendments, within [***] days of request by Hospital. Hospital agrees to treat any and all such Affiliate Agreements in accordance with the provisions of Appendix C.

		
	(d)
	Sublicenses.  Each sublicense granted hereunder shall (a) be consistent with and comply with all of the applicable terms of this Agreement, (b) incorporate any of the terms of this Agreement that are necessary to enable Company to comply with its obligations under this Agreement and (c) provide that Hospital (and Harvard, to the extent that Media Rights are the subject of such sublicense) is a third party beneficiary of any of the terms thereof to the extent necessary to enable Company to comply with its obligations under this Agreement. Company shall notify Hospital, in confidence, of its (or any of its Sublicensees’) intent to enter into a sublicense agreement, and shall provide Hospital with the name of prospective Sublicensee at least [***] days prior to the execution of a sublicense. In fulfilling its reporting obligations under Section 5.1 of this Agreement, Company shall provide notice to Hospital of any executed sublicense and, if requested by Hospital, provide Hospital with a fully signed 

Page 9 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

non-redacted copy of any sublicense agreement (including further sublicenses entered into by Sublicensees) and amendments thereto, including all exhibits, attachments and related documents, within [***] after said request by Hospital. Hospital agrees to treat any and all such sublicense agreements, and any information provided by Company to Hospital in preparation for or anticipation of any such sublicense, in accordance with the provisions of Appendix C; provided, that, Hospital  may disclose any such information provided by Company to Harvard in preparation for or anticipation of any such sublicense to the extent such information relates to a sublicense of the Media Patent Rights, and provided that Hospital shall ensure Harvard’s compliance with the provisions of Appendix C. Upon termination of this Agreement or any license granted hereunder for any reason, any sublicenses shall be addressed in accordance with Section 10.7. Any sublicense which is not in accordance with the forgoing provisions shall be null and void.
2.2    Retained Rights; Requirements.  Any and all licenses granted hereunder are subject to:
		
	(a)
	the right of Hospital and Hospital’s Affiliates as listed in Appendix D to make and to use the subject matter described and/or claimed in the Patent Rights for research and educational purposes; and

		
	(b)
	the right of Hospital and Hospital’s Affiliates as listed in Appendix D to purchase Products and Processes from Company or any of its Affiliates or Sublicensees for use by Hospital and such listed Affiliates as Clinical End Users at a cost reasonably similar to other Clinical End Users in the Northeast region, subject to supply terms and conditions to be reasonably negotiated upon Hospital’s request; and

		
	(c)
	for Patent Rights supported by federal funding, the rights, conditions and limitations imposed by U.S. law (see 35 U.S.C. § 202 et seq. and regulations pertaining thereto), including without limitation:

		
	(i)
	the royalty-free non-exclusive license granted to the U.S. government; and

		
	(ii)
	the requirement, as described and limited at 35 U.S.C. § 202 et seq., that any Products used or sold in the United States are manufactured substantially in the United States; and

		
	(d)
	the right of Harvard, Hospital and Hospital's Affiliates and academic, government and not-for-profit institutions to make and to use the subject matter described and/or claimed in the Media Patent Rights for research and educational purposes and not for the purpose of commercial manufacture, commercial marketing, commercial sale, commercial distribution or provision of services for a fee. 

Page 10 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

For the avoidance of doubt, nothing in this Section 2.3 shall be construed as permitting Hospital, Harvard, Hospital’s Affiliates and/or any such institution or not-for-profit research organization to grant rights to Patent Rights within the scope of the licenses granted above to any for-profit sponsor, or to use Patent Rights to conduct clinical research and/or trials.
2.3    No Additional Rights.  It is understood that nothing in this Agreement shall be construed to grant Company or any of its Affiliates a license, express or implied, under any patent owned solely or jointly by Hospital or Harvard other than the Patent Rights expressly licensed hereunder.  Hospital and/or Harvard shall have the right to license any Media Patent Rights to any other party for any purpose outside of the Limited Field.
2.4    Disclosure of Technological Information.  At Company’s request prior to execution of this Agreement, Hospital (through Dr. Tilly) shall use reasonable efforts to disclose in confidence within [***] days after execution of this Agreement the Technological Information licensed hereunder.
3.      DUE DILIGENCE OBLIGATIONS
3.1    Diligence Requirements.  Company shall use, and shall cause its Affiliates and Sublicensees, as applicable, to use, Commercially Reasonable Efforts to develop and make available to the public Products and Processes throughout the License Territory in the License Field and the Limited Field.  For the avoidance of doubt, subject to Section 12.15 of this Agreement, Company shall be deemed to have achieved such Commercially Reasonable Efforts by achieving the following objectives within the time periods designated below:
		
	(a)
	Pre-Sales Requirements for Product and/or Processes using Hospital Patent Rights and/or Technological Information within License Field.

		
	(i)
	Company shall use Commercially Reasonable Efforts to carry out development of Products and/or Processes within License Field in accordance with development plans mutually agreed by the Parties. 

		
	(ii)
	Company shall secure venture capital or other equity financing of at least $[***] within [***] months following the Original Agreement Effective Date.

		
	(iii)
	Company shall identify one or more study site(s) for a Clinical Proof of Concept study within [***] months following the Original Agreement Effective Date.

		
	(iv)
	Company shall provide a written report to Hospital detailing regulatory strategy for developing a Product or Process within License Field within [***] months following the Original Agreement Effective Date.

Page 11 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(v)
	Company shall enroll the first patient in a Clinical Proof of Concept study within [***] months following the Original Agreement Effective Date.

		
	(vi)
	Company shall (a) complete a Clinical Proof of Concept study within [***] months following the Original Agreement Effective Date; provided, that, this milestone shall be deemed achieved by the completion of a study prospectively intended to demonstrate Clinical Proof of Concept whether or not Clinical Proof of Concept is achieved with such study; or (b) pay [***] ($[***]) to Hospital by the first anniversary of the Restated Effective Date in full satisfaction of Section 4.4(a)(i). 

		
	(vii)
	Company shall develop and present to Hospital development plan for the development of Products and/or Processes within the License Field within [***] following the Original Agreement Effective Date. 

		
	(viii)
	Company shall, as it relates to Hospital Patent Rights or Technological Information within the License Field:

		
	(A)
	use Commercially Reasonable Efforts to achieve a First Commercial Sale within [***] months following the Original Agreement Effective Date (with such efforts within such time defined hereinafter as “Effect First Commercial Sale”) in at least one country in North America;

		
	(B)
	Effect First Commercial Sale in at least one country in Central America or South America;

		
	(C)
	Effect First Commercial Sale in at least one country in the Middle East;

		
	(D)
	Effect First Commercial Sale in at least two countries in Asia Pacific;

		
	(E)
	Effect First Commercial Sale in at least two countries in the European Union (which term shall be deemed under this Agreement to include any members of, or candidates for, the European Union as of the Original Agreement Effective Date); and

		
	(F)
	achieve First Commercial Sale in the United States within [***]

Page 12 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(b)
	Pre-Sales Requirements for Product and/or Processes using Media Patent Rights within the Limited Field: 

		
	(i)
	Company shall, as it relates to Media Patent Rights within the Limited Field:

		
	(A)
	initiate ex vivo animal studies of a Product or Process using the Media Patent Rights within [***] months following the Original Agreement Effective Date;

		
	(B)
	initiate ex vivo human studies of a Product or Process using the Media Patent Rights within [***] months following the Original Agreement Effective Date;

		
	(C)
	achieve First Commercial Sale of a Product or Process using the Media Patent Rights within [***] months following the Original Agreement Effective Date.

		
	(c)
	Post-Sales Requirements for each of the Licensed Field and Limited Field.

		
	(i)
	Following Company’s achievement of any First Commercial Sale satisfying in full its obligations under any of Sections 3.1(a)(viii)(A)-(F) Company shall, either directly or through its Affiliates and/or Sublicensees and/or Distributors:

		
	(A)
	make continuing Sales in North America without any elapsed time period of [***] or more years in which such Sales do not occur, commencing upon the date that First Commercial Sale is made in at least one country in North America; 

		
	(B)
	make continuing Sales in Central America or South America without any elapsed time period of [***] or more years in which such Sales do not occur, commencing upon the date that First Commercial Sale is made in at least one country in Central America or South America;

		
	(C)
	make continuing Sales in the Middle East without any elapsed time period of [***] or more years in which such Sales do not occur, commencing upon the date that First Commercial Sale is made in at least one country in the Middle East;

		
	(D)
	make continuing Sales in Asia Pacific without any elapsed time period of [***] or more years in which such Sales do not occur, commencing upon the date that First Commercial Sale is made in at least two countries in Asia Pacific;

Page 13 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(E)
	make continuing Sales in the European Union without any elapsed time period of [***] or more years in which such Sales do not occur, commencing upon the date that First Commercial Sale is made in at least two countries in the European Union; and

		
	(F)
	make continuing Sales the United States without any elapsed time period of [***] or more years in which such Sales do not occur.

Provided, however, that any such two year period shall be tolled pending the resolution of any event, condition or circumstance that constitutes an Excusable Delay with respect to any country in which a First Commercial Sale was made by the Company in satisfaction of its obligations under Sections 3.1(a)(viii)(A)-(F). 

		
	(ii)
	Following Company’s achievement of a first commercial Sale satisfying in full its obligations under Section 3.1(b)(i)(C), Company shall, directly or through its Affiliates and/or Sublicensees and/or Distributors, make continuing Sales of such Product or Process without any elapsed time period of [***] years or more in which such Sales do not occur, provided, that, to the extent that any such elapsed time is attributable to an Excusable Delay, such [***] year period shall be tolled pending the resolution of the event, condition or circumstance that constitutes such Excusable Delay.

		
	(iii)
	Company shall commit at least [***] Dollars ($[***]) towards the research and development of Product and/or Processes directly related to the License Field, annually, in each calendar year in the range from 20[***] through 20[***].

3.2    Diligence Failures.  
		
	(a)
	If Company is in material breach of its obligations under Section 3.1(a)(ii) through (vii), then, subject to the notice and cure provisions of Section 10.4, Hospital may treat such failure as a default and, at Hospital’s option, may, solely with respect to the country(-ies) to which such material breach directly relates, either terminate or convert the applicable License under 2(a)(i) and/or 2(a)(ii) to non-exclusive.

		
	(b)
	If Company is in material breach of its obligations under Section 3.1(c)(vi)(A)-(F), then, subject to the notice and cure provisions of Section 10.4, Hospital may treat such failure as a default and, at Hospital’s option, may, solely with respect to the country(-ies) to which such material breach directly relates, either terminate or convert the applicable License under 2(a)(i) and/or 2(a)(ii) to non-exclusive.

		
	(c)
	Notwithstanding anything herein to the contrary, Company may, in its sole discretion, unilaterally extend any diligence obligation in Section 3.1 above 

Page 14 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

for an additional period of [***] months by providing written notice to Hospital, which notice shall identify the applicable diligence obligation to be extended, and paying Hospital a fee in the amount of [***] dollars ($[***]); provided, that, any specific diligence obligation may only be unilaterally extended by Company pursuant to this Section 3.2(c) on two separate occasions.  
3.3    Diligence Reports.  Company shall provide all reports with respect to its obligations under Section 3.1 as set forth in Section 5.
4.      PAYMENTS AND ROYALTIES
4.1    License Issue Fees.  
		
	(a)
	License Issue Fee. Company shall pay Hospital a non-refundable license issue fee in the amount of [***] dollars ($[***]) upon execution of this Agreement.

		
	(b)
	Media Patent Rights License Issue Fee. Company shall pay Hospital an additional non-refundable license issue fee in the amount of [***] dollars ($[***]) upon the effective date of Amendment No. 1 to the Original Agreement for the grant of rights under the Media Patent Rights. 

4.2    Patent Cost Reimbursement.  Company shall reimburse Hospital for all costs associated with the preparation, filing, prosecution and maintenance of all Patent Rights ("Patent Costs"). As of the Original Agreement Effective Date, Hospital has incurred approximately [***] Dollars ($[***]) in Patent Costs with respect to Hospital Patent Rights. As of the effective date of Amendment No. 1 to the Original Agreement, Hospital and Harvard have incurred approximately Thirteen Thousand Dollars ($13,000.00) in Patent Costs with respect to Media Patent Rights. Company shall pay such amounts to Hospital based upon the following schedule: 
		
	•
	$[***] within [***] days of the [***]

		
	•
	All Patent Costs with respect to Media Patent Rights within [***] days after the effective date of Amendment No. 1 to the Original Agreement

		
	•
	$[***] on the [***] anniversary of the [***]

		
	•
	[***] on the [***] anniversary of the Original Agreement Effective Date

Company shall pay to Hospital, or at Hospital's request directly to patent counsel, all other Patent Costs within [***] days of Company’s receipt of an invoice for such Patent Costs either from Hospital or Hospital’s patent counsel. Hospital shall instruct patent counsel to provide copies to Hospital for Hospital’s administrative files of all invoices detailing Patent Costs which are sent directly to Company.

4.3    Annual License Fee; Annual Maintenance Fee. 

Page 15 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(a)
	Annual License Fee.  Company shall pay to Hospital the non-refundable amount of [***] Dollars ($[***]) as an annual license fee (the “Annual License Fee”) within [***] days after each of the first (1st) and second (2nd) anniversaries of the Original Agreement Effective Date; provided that such Annual License Fee shall increase to [***] Dollars ($[***]) as of July 30, 2013 and become payable upon the third (3rd) anniversary of the Original Agreement Effective Date and each subsequent anniversary thereafter.

The first [***] Dollars ($[***]) of the Annual License Fees shall be creditable against royalties subsequently due on Net Sales amounts made during the [***] and [***] calendar years following the Original Agreement Effective Date, if any, but shall not be credited against royalties due on Net Sales made in any other subsequent year.
		
	(b)
	Annual Maintenance Fee.  Beginning on the third (3rd) anniversary of the Original Agreement Effective Date, Company shall pay the amount of [***] Dollars ($[***]) as an annual maintenance fee (the “Annual Maintenance Fee”) to Hospital within [***] days after each anniversary of the Original Agreement Effective Date.  The Annual Maintenance Fee shall be non-refundable and non-creditable against royalties. Except as provided for in Section 4.3(e) below, the Annual Maintenance Fee shall be non-refundable.

		
	(c)
	Media Patent Rights Annual License Fee. Company shall pay to Hospital the non-refundable amount of [***] Dollars ($[***]) as an annual license fee for the grant of rights under the Media Patent Rights (the “Media Patent Rights Annual License Fee”) within [***] days after each anniversary of the Original Agreement Effective Date. 

		
	(d)
	Crediting of Media Patent Rights Annual License Fee.  Each Media Patent Rights Annual License Fee shall be creditable against royalties subsequently due on Net Sales amounts from Products or Processes relying on the Media Patent Rights made in the same year as such fee is due, and against milestones subsequently due in the same year as such fee is due, but shall not be credited against royalties due on Net Sales made or milestones payable in any other subsequent year. However, the first [***] Dollars ($[***]) of Media Patent Rights Annual License Fees shall be creditable against royalties subsequently due on Net Sales amounts made and milestones payable during the [***] and [***] calendar years following the Original Agreement Effective Date, if any, but shall not be credited against royalties due on Net Sales made or milestones payable in any other prior or subsequent year. 

		
	(e)
	Crediting of Annual Maintenance Fee.  [***] Dollars ($[***]) of the Annual Maintenance Fee shall be creditable against royalties subsequently due on Net Sales amounts from Products or Processes relying on the Hospital Patent Rights within the License Field made in the same year as such Annual Maintenance Fee is due, and against milestones subsequently due in the same year as such Annual Maintenance Fee is due, but shall not be credited against 

Page 16 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

royalties due on Net Sales made or milestones payable in any other subsequent year.
4.4    Milestone Payments.  
		
	(a)
	In addition to the payments set forth in Sections 4.1 through 4.3 above, Company shall pay Hospital the following milestone payments, which shall be due and payable as set forth in Section 4.4(c) below:

		
	(i) 
	[***] Dollars ($[***]) (i) within [***] days of achieving Clinical Proof of Concept, or (ii) on the [***] anniversary of the Restated Effective Date, performance of either one of (i) and (ii) shall constitute full satisfaction of Section 3.1(a)(vi); and

		
	(ii)
	[***] Dollars ($[***]) on the [***] and/or [***] and/or [***]; and

		
	(i)
	[***] Dollars ($[***]) on the [***] and/or [***] and/or [***]; and

		
	(iv)
	[***] Dollars ($[***]) on the date of [***]; and

		
	(v)
	[***] Dollars ($[***]) on the date of [***]; and

		
	(i)
	[***] Dollars ($[***]) on the date of [***] and/or [***]; and

		
	(vii)
	[***] Dollars ($[***]) on the earlier of (i) the date of [***] and/or [***] or (ii) [***] months after the date of [***] and/or [***]; and 

		
	(viii)
	[***] Dollars ($[***]) on the date in the first calendar year in which Net Sales amounts equal or exceed [***] Dollars ($[***]); and

		
	(ix)
	[***] Dollars ($[***]) on the date in the first calendar year in which Net Sales amounts equal or exceed [***] Dollars ($[***]); and

		
	(x)
	[***] Dollars ($[***]) on the date in the first calendar year in which Net Sales amounts equal or exceed [***] Dollars ($[***]); and

		
	(xi)
	[***] Dollars ($[***]) on the date in the first calendar year in which Net Sales amounts equal or exceed [***] Dollars ($[***]); and

		
	(xii)
	[***] Dollars ($[***]) on the date in the first calendar year in which Net Sales amounts equal or exceed [***] Dollars ($[***]); and

		
	(xiii)
	[***] Dollars ($[***]) on the date in the first calendar year in which Net Sales amounts equal or exceed [***] Dollars ($[***]); and

		
	(xiv)
	[***] Dollars ($[***]) on the date in the first calendar year in which Net Sales amounts equal or exceed [***] Dollars ($[***]).

Page 17 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(b)
	For the avoidance of doubt, should the milestone described in clause (vii) above be achieved before the milestone in clause (vi) above is achieved, the milestone payments described in clause (vi) will be due and payable concurrently with the milestone payment described in clause (vii), and should Net Sales amounts be equal to or greater than more than one of the above as yet to be achieved milestones in any given calendar year, all such milestones first achieved in such calendar year shall be due for that calendar year.

		
	(a)
	All payments due to Hospital under this Section 4.4 shall be due and payable by Company within [***] days after the end of each Reporting Period, and shall be accompanied by a report as set forth in Sections 5.2 and 5.3. The milestone payments set forth in this Section 4.4 shall each be payable no more than once.

4.5    Royalties and Sublicense Income. 
		
	(a)
	Royalty Payments in the License Field. Beginning with the First Commercial Sale of any Product or Process in the License Field, Company shall pay Hospital during the term of any license granted under Section 2.1(a)(i), a royalty of: (i) [***] percent ([***]%) of the Net Sales amounts of all Products or Processes for all human applications and (ii) [***] percent ([***]%) of the Net Sales amounts of all Products and Processes for all animal applications. In the event that Company reasonably determines that royalty payments to one or more third parties are required in order to avoid potential infringement of third party patent rights, Company shall notify Hospital via Hospital’s Chief Innovation Officer promptly following Company’s decision to pursue a license from the applicable third party and, if such payments are in excess of [***] percent ([***]%) of Net Sales, Company may offset a total of [***] percent ([***]%) of such third-party payments that are due under this Section 4.5(a) to Hospital in the same Reporting Period.  Without limiting the foregoing, in connection with providing notification to Hospital of Company’s intent to pursue a third party license, Company shall provide an explanation of its rationale for pursuing the license.  In the event that Hospital notifies Company that Hospital has concerns regarding Company’s determination to seek such license, the Parties shall be convened to review the determination. Failing satisfactory resolution from the Parties, the matter shall be discussed between Company’s CEO or Chairman and the Hospital’s Director of Innovation; provided that, Company’s CEO shall have final decision-making authority with respect to such matter and Company shall not be required to delay obtaining the proposed third party license for more than [***] days in total as a result of the foregoing review and executive consultation process. 

		
	(b)
	Royalty Payments in the Limited Field.  Beginning with the First Commercial Sale of any Product or Process in the Limited Field, Company 

Page 18 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

shall pay Hospital during the term of any license granted under Section 2.1(a)(ii) with respect to Hospital’s and Harvard’s rights in and to Media Patent Rights in the Limited Field, a royalty of (i) [***] percent ([***]%) of the Net Sales amounts of all Products or Processes for all human applications and (ii) [***] percent ([***]%) of the Net Sales amounts of all Products or Processes for all animal applications in the Limited Field. Notwithstanding anything to the contrary in this Section 4.5(b), to the extent that any Product or Process is directly covered by an issued Claim of the Media Patent Rights in any country in which such Product or Process is being sold by Company (each, a “Media Royalty-Bearing Product”) then, commencing on the date of expiration of such issued Claim(s) and for a period of [***] months thereafter, Company shall pay Hospital a royalty of (i) [***] percent ([***]%) of the Net Sales of Media Royalty-Bearing Products for all human applications in the Limited Field; and (ii) [***] percent ([***]%) of the Net Sales of Media Royalty-Bearing Products for all animal applications in the Limited Field. 
		
	(c)
	Royalty Adjustment Floor.  Notwithstanding anything to the contrary in this Agreement, (i) in no event will the royalty payments under Section 4.5(a) be reduced by more than [***] percent ([***]%) in any given calendar year as a result of the application to a given Product or Process of the reductions set forth in both Section 1.15(g) and Section 4.5(b) and (ii) in no event will the royalty payments under Section 4.5(a) be reduced by more than [***] percent ([***]%) in any given calendar year as a result of the application to a given Product or Process of the reductions set forth in either Section 1.15(g) or Section 4.5(b). 

		
	(d)
	Sublicense Income Payments.

		
	(i)
	Company shall pay Hospital a percentage of any Sublicense Income received by Company according to the following schedule:

	
		
	Date of Receipt of Sublicense Income
	Percentage of Sublicense Income due to Hospital

	[***]
	[***] %

	[***]
	[***] %

	[***]
	[***] %

	[***]
	[***] %

Page 19 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(ii)
	Notwithstanding anything to the contrary in Section 4.5(d)(i), the: 

 (A) percentage of Sublicense Income due to Hospital on [***] will only be adjusted to [***]% as provided in Section 4.5(d)(i) if Company pays Hospital a non-refundable, non-creditable buy-down fee of [***] Dollars ($[***]) upon the Restated Effective Date, otherwise it shall remain [***]%; and
(B) percentage of Sublicense Income due to Hospital on [***] will only be adjusted to [***]% as provided in Section 4.5(d)(i) if Company pays Hospital a non-refundable, non-creditable buy-down fee of [***] Dollars ($[***]) upon the first anniversary of the Restated Effective Date.
		
	(i)
	All payments due to Hospital under this Section 4.5 shall be due and payable by Company within [***] days after the end of each Reporting Period, and shall be accompanied by a report as set forth in Sections 5.3 and 5.4.

4.6    Liquidity Event Milestone Fee.  Company shall pay Hospital [***] Dollars ($[***]) (the “Liquidity Event Fee”), within [***] days following the first to occur of the following: 
		
	(a)
	The closing of the first (1st) sale by the Company of originally issued securities of the Company on or after [***] 20[***] (an “IPO”); provided that, if the proceeds to the Company from such IPO are less than [***] Dollars ($[***]), Company shall pay one percent ([***]%) of such proceeds to Hospital within [***] days following such closing, and thereafter on each anniversary of such closing, shall pay to Hospital the lesser of [***] percent ([***]%) of such proceeds or the payment amount that, when combined with prior payments pursuant to this Section 4.6(a), would equal [***] Dollars ($[***]); or

		
	(b)
	[***] 20[***]; or

		
	(c)
	The closing of the first to occur of any of the following transactions (each, a “Change of Control”):

		
	(i)
	a sale, conveyance or other disposition of all or substantially all of the assets of the Company (other than to an Affiliate of Company as part of a reorganization or restructuring); or

		
	(ii)
	a merger or consolidation of Company with or into any other entity, unless the stockholders of Company immediately before the transaction own fifty 

Page 20 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

percent (50%) or more of the voting or capital stock of the acquiring or surviving corporation following the transaction;
provided that if the proceeds to the Company of such Change of Control are less than [***] Dollars ($[***]), Company shall pay to Hospital [***] Dollars ($[***]) within [***] days following such Change of Control and thereafter shall pay to Hospital [***] ($[***]) on each of the first three (3) anniversaries of such Change of Control.
Provided, however, that this Section 4.6 shall terminate upon the full payment of the Liquidity Event Fee.
4.7    Form of Payment.  All payments due under this Agreement shall be drawn on a United States bank and shall be payable in United States dollars.  Each payment shall reference this Agreement and its Agreement Number and identify the obligation under this Agreement that the payment satisfies.  Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States, as reported in The Wall Street Journal, on the last working day of the applicable Reporting Period.  Such payments shall be without deduction of exchange, collection or other charges, and, specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes, except as legally required or permitted in the definition of Net Sales.
Checks for all payments due to the Hospital under this Agreement shall be made payable to the Hospital and addressed as set forth below:
Massachusetts General Hospital 
BOA-Lockbox Services 
PCSR Lockbox #[***]  
MA5-527-02-07 
2 Morrissey Blvd 
Dorchester, MA 02125  
Reference Agreement #: A209968 
Payments via wire transfer should be made as follows:
ACH Credit: ABA # 011-000-138  
Federal Reserve Wire: ABA#026-009-593  
SWIFT Code: BOFAUS3N  
Account #[***]  
Massachusetts General Hospital  
Bank of America 
100 Federal Street  
Boston, MA 02110  
Reference Agreement #: A209968

Page 21 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

4.8    Overdue Payments.  The payments due under this Agreement shall, if overdue, bear interest beginning on the first day following the Reporting Period to which such payment was incurred and until payment thereof at a per annum rate equal to two percent (2%) above the prime rate in effect on the due date as reported by The Wall Street Journal, such interest rate being compounded on the last day of each Reporting Period, not to exceed the maximum permitted by law.  Any such overdue payments when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not preclude Hospital from exercising any other rights it may have as a consequence of the lateness of any payment.
5.      REPORTS AND RECORDS
5.1    Diligence Reports.  Within [***] days after the end of each calendar year until such time as a First Commercial Sale has been achieved in the United States and the objectives set forth in Section 3.1 (b) have been achieved, Company shall report in writing to Hospital on progress made toward such objectives during such preceding 12 month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
5.2    Milestone Achievement Notification.  Company shall, along with delivering payment as set forth in Section 4.7, report to Hospital the dates on which it achieves the milestones set forth in Section 4.4 within [***] days after the Reporting Period during which each such milestone was achieved.
5.3    Sales Reports.  Company shall report to Hospital the date on which it achieves the First Commercial Sale in each country of the License Territory within [***] days of each such occurrence.  Following the First Commercial Sale, Company shall deliver reports to Hospital within [***] days after the end of each Reporting Period.  Each report under this Section 5.3 shall have substantially the format outlined in Appendix E, shall be certified as correct by an officer of Company and shall contain at least the following information (or as otherwise determined by the Parties) as may be pertinent to a royalty accounting hereunder for the immediately preceding Reporting Period:
		
	(a)
	the number of Products and Processes Sold by Company, its Affiliates and Sublicensees in each of (i) the United States, (ii) the European Union, (iii) Japan and (iv) all other countries in aggregate (each of (i), (ii), (iii) and (iv), a “Reporting Territory”);

		
	(b)
	the amounts billed or invoiced by Company, its Affiliates and Sublicensees for each Product and Process, in each Reporting Territory, and total billings due for all Products and Processes;

		
	(c)
	calculation of Net Sales for the applicable Reporting Period in each Reporting Territory, including an itemized listing of permitted offsets and deductions;

Page 22 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(d)
	total royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and

		
	(e)
	any other payments due to Hospital under this Agreement.

If no amounts are due to Hospital for any Reporting Period, the report shall so state.
In addition to the above, in each such report, Company shall separately account (i) for royalties owed for Net Sales of Products and/or Processes covered solely by Media Patent Rights and solely by Hospital Patent Rights and (ii) for royalties owed for Net Sales of Products and/or Processes covered by both Media Patent Rights and Hospital Patent Rights. Such reporting shall be of sufficient detail as to how the separate royalties were calculated in relation to (ii) above. Absent the Company's ability to accurately determine the royalties for each of the Hospital Patent Rights and Media Patent Rights as they relate to Products and/or Processes covered by both Media Patent Rights and Hospital Patent Rights, Company shall specify in its independent, good faith discretion the amount of such royalties attributable to the Media Patent Rights.
5.4    Sublicense Income Reports.  Company shall, along with delivering payment as set forth in Section 4.7, report to Hospital within [***] days after the end of each Reporting Period the amount of all Sublicense Income received by Company during such Reporting Period, and Company's calculation of the amount due and paid to Hospital from such income, including an itemized listing of the source of income comprising such consideration, and the name and address of each entity making such payments in substantially the format outlined in Appendix F. Additionally, Company shall separately account for Sublicense Income owed with respect to the Hospital Patent Rights and the Media Patent Rights. Absent Company's ability to accurately determine the Sublicense Income with respect to the each of the Hospital Patent Rights and Media Patent Rights, Company shall specify in its independent, good faith discretion the amount of such Sublicense income attributable to the Media Patent Rights.
5.5    Audit Rights.  Company shall maintain, and shall cause each of its Affiliates and Sublicensees to maintain, complete and accurate records relating to the rights and obligations under this Agreement and any amounts payable to Hospital in relation to this Agreement, which records shall contain sufficient information to permit Hospital and its representatives to confirm the accuracy of any payments and reports delivered to Hospital and compliance in all other respects with this Agreement.  Company shall retain and make available, and shall require each of its Affiliates and Sublicensees to retain and make available, such records for at least [***] years following the end of the calendar year to which they pertain, to Hospital and/or its representatives and upon at least [***)] days’ advance written notice, for inspection during normal business hours, to verify any reports and payments made and/or compliance in other respects under this Agreement.  If any examination conducted by Hospital or its representatives pursuant to the provisions of this Section show an underreporting or underpayment of [***] percent ([***]%) or more in any calendar year due to Hospital hereunder, then, subject to Company’s right to discuss or dispute the results of such examination, including obtaining a report from a mutually agreed upon auditor, which results would be binding upon both parties, Company shall bear the full cost of such audit and shall remit any amounts due to Hospital 

Page 23 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

(including interest due in accordance with Section 4.8) within [***] days of receiving notice thereof from Hospital.
6.      PATENT PROSECUTION AND MAINTENANCE
6.1    Prosecution.  Hospital shall be responsible for the preparation, filing, prosecution and maintenance of all patent applications and patents included in Patent Rights.  Company shall reimburse Hospital for Patent Costs incurred by Hospital relating thereto in accordance with Section 4.2; provided that Hospital and Company shall discuss and agree in advance on the countries in which Hospital will prosecute the Patent Rights, so that Company may elect in advance, pursuant to Section 6.3, not to pay costs for any countries in which Company does not desire to fund such prosecution.
6.2    Copies of Documents.  With respect to any Patent Right licensed hereunder, Hospital shall instruct the patent counsel prosecuting such Patent Right to (i) copy Company on patent prosecution documents that are received from or filed with the United States Patent and Trademark Office and foreign equivalent, as applicable; (ii) if requested by Company, provide Company with copies of draft submissions to the USPTO prior to filing; and (iii) give consideration to the comments and requests of Company or its patent counsel.
6.3    Company’s Election Not to Proceed.  Company may elect to surrender any patent or patent application in Patent Rights in any country upon [***] days advance written notice to Hospital.  Such notice shall relieve Company from the obligation to pay for future Patent Costs but shall not relieve Company from responsibility to pay Patent Costs actually incurred prior to the expiration of the [***] day notice period.  Such U.S. or foreign patent application or patent shall thereupon cease to be a Patent Right hereunder, Company shall have no further rights therein and Hospital shall be free to license its rights to that particular U.S. or foreign patent application or patent to any other party on any terms.
6.4    Confidentiality of Prosecution and Maintenance Information.  Company agrees to treat all information related to prosecution and maintenance of Patent Rights as Confidential Information in accordance with the provisions of Appendix C. Additionally, Hospital agrees to treat all information provided by or on behalf of Company related to its prosecution strategy as Confidential Information in accordance with the provisions of Appendix C.
7.      THIRD PARTY INFRINGEMENT AND LEGAL ACTIONS
7.1    Hospital Right to Prosecute.  Hospital will protect the Patent Rights from infringement and prosecute infringers when, in its sole judgment, such action may be reasonably necessary, proper and justified.  If Company shall have supplied Hospital with prima facie infringement of a claim of a Hospital Patent Right in the License Field, or of a Media Patent Right in the Limited Field, in each case in the License Territory by a third party which poses a material threat to Company’s rights under this Agreement, Company may by notice request Hospital to take steps to protect such Patent Right.  Hospital shall notify Company within [***] days of the receipt of such notice whether Hospital intends to prosecute the alleged infringement.  If Hospital notifies Company that it intends to so prosecute, Hospital shall, within [***] months of its notice to 

Page 24 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Company either (a) cause such infringement to terminate, or (b) initiate legal proceedings against the infringer.
7.2    Company Right to Prosecute.  In the event Hospital notifies Company that Hospital does not intend to prosecute infringement identified under Section 7.1 or otherwise fails to cause such infringement to terminate or initiate legal proceedings against the infringer within three (3) months, Company may, upon notice to Hospital, initiate legal proceedings against the infringer at Company’s expense with respect to a claim of a Hospital Patent Right in the License Field, or of a Media Patent Right in the Limited Field, in the License Territory.  Before commencing such action, Company and, as applicable, any Affiliate, shall consult with Hospital, concerning, among other things, Company’s standing to bring suit, the selection of counsel and the jurisdiction for such action and shall consider the views of Hospital regarding the proposed action, including, without limitation with respect to potential effects on the public interest.  Company shall be responsible for all costs, expenses and liabilities in connection with any such action and shall indemnify and hold Hospital and Harvard harmless therefrom, regardless of whether Hospital or Harvard is a party-plaintiff, except for the expense of any independent counsel retained by Hospital in accordance with Section 7.5 below.
7.3    Hospital and/or Harvard Joined as Party-Plaintiff.  If Company elects to commence an action as described in Section 7.2 above, Hospital and/or Harvard shall have, in its sole discretion, the option to join such action as a party-plaintiff. If joinder of Hospital and/or Harvard as a party-plaintiff is necessary or desirable in order for Company to bring or maintain such action or to prove damages in such action, and Company requests that Hospital and/or Harvard be joined, Hospital and/or Harvard may either, in its sole discretion, permit itself to be joined as a party-plaintiff at the sole expense of Company, or assign to Company all of Hospital’s and/or Harvard’s right, title and interest in and to the Patent Right which is the subject of such action (subject to all of Hospital’s and/or Harvard’s obligations to the government under law and any other rights that others may have in such Patent Right).  If Hospital and/or Harvard makes such an assignment, such action by Company shall thereafter be brought or continued without Hospital and/or Harvard as a party; provided, however, that Hospital and/or Harvard shall continue to have all rights of prosecution and maintenance with respect to Patent Rights and Company shall continue to meet all of its obligations under this Agreement as if the assigned Patent Right were still licensed to Company hereunder.
7.4    Notice of Actions; Settlement.  Company shall promptly inform Hospital of any action or suit relating to Patent Rights and shall not enter into any settlement, consent judgment or other voluntary final disposition of any action relating to Patent Rights, including but not limited to appeals, without the prior written consent of Hospital and/or Harvard, as applicable.
7.5    Cooperation.  Each Party agrees to cooperate reasonably in any action under Section 7 which is controlled by the other Party, provided that the controlling Party reimburses the cooperating Party for any costs and expenses incurred by the cooperating Party in connection with providing such assistance, except for the expense of any independent counsel retained by the cooperating Party in accordance with this Section 7.5.  Such controlling Party shall keep the cooperating Party informed of the progress of such proceedings and shall make its counsel 

Page 25 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

available to the cooperating Party.  The cooperating Party shall also be entitled to independent counsel in such proceedings but at its own expense, said expense to be offset against any damages received by the Party bringing suit in accordance with Section 7.6.
7.6    Recovery.  Any award paid by third parties as the result of such proceedings (whether by way of settlement or otherwise) shall first be applied to reimbursement of any legal fees and expenses incurred by either Party and then the remainder shall be divided between the Parties as follows:
		
	(i)
	Company shall receive an amount equal to its lost profits or a reasonable royalty on the infringing sales, or whichever measure of damages the court shall have applied; and

		
	(ii)
	Hospital shall receive an amount equal to the royalties and other amounts that Company would have paid to Hospital if Company had Sold the infringing Products and Services rather than the infringer; and

		
	(iii)
	the balance, if any, remaining after Company and Hospital have been compensated under Section 7.6(a) shall be shall be shared [***] percent ([***]%) to the controlling party and [***] ([***]%) to the cooperating party.

8.      INDEMNIFICATION AND INSURANCE
8.1    Indemnification.
		
	(a)
	Company shall indemnify, defend and hold harmless Hospital and Harvard and their Affiliates and their respective current or former trustees, directors, officers, medical and professional staff, governing board members, faculty, students, employees, and agents and their respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss or expense (including reasonable attorney's fees and expenses of litigation incurred by or imposed upon the Indemnitees or any one of them in connection with any claims, suits, actions, demands or judgments of any third party arising out of any theory of product liability (including, but not limited to, actions in the form of contract, tort, warranty, or strict liability) concerning any Product, Process or service made, used, or sold or performed pursuant to any right or license granted under this Agreement. The previous sentence will not apply to any third party claim that is determined to result from the gross negligence or willful misconduct of an Indemnitee or from any breach of any obligation of Hospital and/or Harvard under this Agreement.

		
	(b)
	With respect to Patent Cost Reimbursement under Section 4.2, Company agrees to indemnify, defend and hold Hospital harmless from and against any and all Patent Costs and costs of collection arising from the failure of Company to timely pay such Patent Costs.

Page 26 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

		
	(c)
	Company agrees, at its own expense, to provide attorneys reasonably acceptable to the Hospital and/or Harvard to defend against any actions brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought; provided, however, that any Indemnitee shall have the right to retain its own counsel, at the expense of Company, if representation of such Indemnitee by counsel retained by Company would be inappropriate because of conflict of interests of such Indemnitee and any other party represented by such counsel. Company agrees to keep Hospital and/or Harvard informed of the progress in the defense and disposition of such claim and to consult with Hospital and/or Harvard prior to any proposed settlement.

		
	(d)
	This Section 8.1 shall survive expiration or termination of this Agreement.

8.2    Insurance.
		
	(a)
	Beginning at such time as any such Product, Process being commercially distributed, sold, leased or otherwise transferred, or performed or used (other than for the purpose of obtaining regulatory approvals), by Company, an Affiliate or Sublicensee, Company shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $[***] per incident and $[***] annual aggregate and naming the Indemnitees as additional insureds.  Such commercial general liability insurance shall provide product liability coverage and shall not have a Contractual Liability Limitation Endorsement.  If Company elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of $[***] annual aggregate) such self-insurance program must be acceptable to the Hospital and the Risk Management Foundation.  The minimum amounts of insurance coverage required under this Section 8.2 shall not be construed to create a limit of Company’s liability with respect to its indemnification under Section 8.1 of this Agreement.

		
	(b)
	Company shall provide Hospital with written evidence of such insurance upon request of Hospital.  Company shall provide Hospital with written notice at least [***] days prior to the cancellation, non-renewal or material change in such insurance; if Company does not obtain replacement insurance providing comparable coverage prior to the expiration of such [***] day period, Hospital shall have the right to terminate this Agreement effective at the end of such [***] day period without notice or any additional waiting periods.

		
	(c)
	Company shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during (i) the period that any such Product, Process, or service is being commercially distributed, sold, leased or otherwise transferred, or performed or used (other than for the 

Page 27 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

purpose of obtaining regulatory approvals), by Company or by a licensee, affiliate or agent of Company and (ii) a reasonable period after the period referred to in (c) (i) above which in no event shall be less than [***] years.
		
	(d)
	This Section 8.2 shall survive expiration or termination of this Agreement.

9.      DISCLAIMER OF WARRANTIES; LIMITATION OF LIABILITY
9.1    Title to Patent Rights.  To the best knowledge of Hospital’s Innovation Office, Hospital is the owner by assignment from Dr. Jonathan Tilly, [***] and Dr. Joshua Johnson of the Hospital Patent Rights, and Hospital and Harvard are the only owners by assignment from Dr. Jonathan Tilly and [***], respectively, of the Media Patent Rights and Hospital has the authority to enter into this Agreement and license the Hospital Patent Rights and the Media Patent Rights to Company hereunder.
9.2    No Warranties.  EXCEPT AS PROVIDED IN SECTION 9.1 ABOVE, NEITHER HOSPITAL NOR HARVARD MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, CONCERNING THE PATENT RIGHTS AND THE RIGHTS GRANTED HEREUNDER, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, AND HEREBY DISCLAIMS THE SAME. SPECIFICALLY, AND NOT TO LIMIT THE FOREGOING, NEITHER HOSPITAL NOR HARVARD MAKES ANY WARRANTY OR REPRESENTATION (a) REGARDING THE VALIDITY OR SCOPE OF ANY OF THE CLAIM(S), WHETHER ISSUED OR PENDING, OF ANY OF THE PATENT RIGHTS, AND (b) THAT THE EXPLOITATION OF THE PATENT RIGHTS OR ANY PRODUCT OR PROCESS WILL NOT INFRINGE ANY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF HOSPITAL, HARVARD OR OF ANY THIRD PARTY.
9.3    Limitation of Liability.  IN NO EVENT SHALL EITHER PARTY OR HARVARD OR ANY OF THEIR RESPECTIVE AFFILIATES OR ANY OF THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, MEDICAL AND PROFESSIONAL STAFF, EMPLOYEES AND AGENTS BE LIABLE TO THE ANOTHER OR ANY OF ITS AFFILIATES FOR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE LICENSE RIGHTS GRANTED HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, INCLUDING WITHOUT LIMITATION SUCH DAMAGES THAT ARE ECONOMIC DAMAGES OR INJURY TO PROPERTY OR LOST PROFITS, REGARDLESS OF WHETHER SUCH ENTITY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING; PROVIDED, HOWEVER, NOTHING IN THIS SECTION 9.3 SHALL BE CONSTRUED TO LIMIT COMPANY'S OBLIGATION TO INDEMNIFY HOSPITAL AND HARVARD UNDER SECTION 8 OF THIS AGREEMENT.

Page 28 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

10.      TERM AND TERMINATION
10.1    Term.  The term of this Agreement shall commence on the Original Agreement Effective Date and shall remain in effect on a Product-by-Product, Process-by-Process and country-by-country basis until the date on which all Claims that cover the applicable Product or Process in the applicable country have expired or been abandoned, unless this Agreement is terminated earlier in accordance with any of the other provisions of Section 10.  Following expiration of this Agreement with respect to a Product or Process in a particular country, as described in the prior sentence, the licenses and rights granted to Company pursuant to Section 2.1 shall remain in effect on a perpetual, royalty-free and non-exclusive basis.
10.2    Termination for Failure to Pay.  If Company fails to make any payment due hereunder, Hospital shall have the right to terminate this Agreement upon [***] days written notice, unless Company makes such payments plus any interest due, as set forth in Section 4.7, within said [***] day notice period.  If payments are not made, Hospital may immediately terminate this Agreement at the end of said [***] day period.  Company shall be entitled to only one such cure period in a calendar year; for a second failure to make payment on time, Hospital shall have the right to terminate this Agreement immediately upon written notice.  Notwithstanding the foregoing, if Company in good faith disputes a payment obligation asserted by Hospital, then, providing Company shall make said disputed payment and Hospital shall place said payment in escrow, such termination right shall be tolled until after such dispute is resolved, and this Agreement shall not terminate based on such dispute if Company pays all amounts ultimately determined to be due within [***] days following the resolution of such dispute in accordance with Section 12.8.
10.3    Termination for Insurance and Insolvency.
		
	(a)
	Insurance.  Hospital shall have the right to terminate this Agreement in accordance with Section 8.2(b) if Company fails to maintain the insurance required by Section 8.2.

		
	(b)
	Insolvency and other Bankruptcy Related Events.  Hospital shall have the right to terminate this Agreement immediately upon written notice to Company with no further notice obligation or opportunity to cure if Company: (i) shall make an assignment for the benefit of creditors; or (ii) or shall have a petition in bankruptcy filed for or against it (provided that in the case of a petition in bankruptcy filed against it, Hospital shall not have the right to terminate this Agreement if such petition is dismissed within sixty (60) days following the filing of such petition).

10.4    Termination for Non-Financial Default.  If Company, any of its Affiliates or any Sublicensee shall materially default in the performance of any of its other obligations under this Agreement not otherwise covered by the provisions of Section 10.2 and 10.3, and if such material default has not been cured within [***] days after notice by Hospital in writing of such default, then, subject to Company’s right to unilaterally extend any diligence obligation as provided in Section 3.2(c) above, Hospital may immediately terminate this Agreement, and/or 

Page 29 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

any license granted hereunder with respect to the country or countries in which such default has occurred, at the end of said [***] day cure period.  Hospital shall also have the right to terminate this Agreement and/or any such license immediately, upon written notice, in the event of [***] or more material defaults in any [***] year period even if cured within such [***] day period.
10.5    Challenging Validity.  During the term of this Agreement, Company shall not challenge, and shall restrict its Affiliates and Sublicensees from challenging the validity of the Patent Rights and, in the event of any breach of this provision by Company, Hospital shall have the right to terminate this Agreement and any license granted hereunder immediately. In addition, if the Patent Rights are upheld, Company shall reimburse Hospital and Harvard for their legal costs and expenses incurred in defending any such challenge by Company or its Affiliates or Sublicensees in any country in which Company and its Affiliates and Sublicensees retain a license to such Patent Rights under this Agreement.
10.6    Termination by Company.  Company shall have the right to terminate this Agreement in its entirety by giving ninety (90) days advance written notice to Hospital and upon such termination shall immediately cease all use and Sales of Products and Processes, subject to Section 10.9.  Company shall also have the right to terminate its license hereunder with respect to the Hospital Patent Rights in the License Field, or the Media Patent Rights in the Limited Field, by giving ninety (90) days advance written notice to Hospital and upon such termination shall immediately cease all use and Sales of Products and Processes using the Hospital Patent Rights in the License Field, or the Media Patent Rights in the Limited Field, as applicable, subject to Section 10.9.  Following such a termination: (a) with respect to the Hospital Patent Rights in the License Field only, Section 3.1(a), and to the extent not already achieved or paid, Sections 4.3(a), 4.3(b), 4.4(a)(ii) and 4.4(a)(iii) shall no longer have any force or effect provided however, in the event any such written notice of termination by Company is received within 90 days prior to or 60 days after any given anniversary of the Original Agreement Effective Date, payments to Hospital pursuant to sections 4.3(a) and 4.3(b) shall be made in accordance with the normal payment schedule provided within those sections; (b) with respect to the Media Patent Rights only, Sections 3.1(b), 3.1(c), and to the extent not already achieved or paid, Sections 4.3(c), 4.4(a)(vi) and 4.4(a)(vii) shall no longer have any force or effect provided however, in the event any such written notice of termination by Company is received within 90 days prior to or 60 days after any given anniversary of the Original Agreement Effective Date, payments to Hospital pursuant to section 4.3(c) shall be made in accordance with the normal payment schedule provided within that section; and (c) except as expressly provided in this Section 10.6, this Agreement shall remain in full force and effect.
10.7    Effect of Termination on Sublicenses.  Any sublicenses granted by Company under this Agreement shall provide for assignment to Hospital of Company’s interest therein, upon termination (but not expiration) of this Agreement or upon termination of any license hereunder under which such sublicense has been granted.  Upon assignment of any such sublicense to Hospital upon termination, the rights granted to the Sublicensee in such sublicense shall survive; provided that, (a) Hospital shall not be obligated to accept the assignment of any such sublicense if the Sublicensee is then in material default of any of the obligations required to be imposed on Sublicensees pursuant to this Agreement and (b) Hospital shall not have any liability for 

Page 30 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Company’s obligations pursuant to the sublicense beyond Hospital’s obligations with respect to the sublicensed rights under this Agreement.
10.8    Effects of Termination of Agreement.  Upon termination of this Agreement or any of the licenses hereunder for any reason, final reports in accordance with Section 5 shall be submitted to Hospital and all royalties and other payments, including without limitation any unreimbursed Patent Costs, accrued or due to Hospital as of the termination date shall become immediately payable.  Company shall cease, and shall cause its Affiliates and require its Sublicensees to cease under any sublicense granted by Company under this Agreement, all Sales and uses of Products and Processes upon such termination (but not expiration), subject to Sections 10.7 and 10.9.  The termination or expiration of this Agreement or any license granted hereunder shall not relieve Company, its Affiliates or Sublicensees of obligations arising before such termination or expiration.
10.9    Inventory.  Upon early termination of this Agreement other than for Company default under Section 10.4, Company, Company Affiliates and Sublicensees may complete and sell any work-in-progress and inventory of Products or Processes that exist as of the effective date of termination, provided that (i) Company pays Hospital the applicable running royalty or other amounts due on such Net Sales amounts in accordance with the terms and conditions of this Agreement, and (ii) Company, Company Affiliates and Sublicensees shall be permitted, but are not required to complete and sell all work-in-progress and inventory of Products within [***] months after the effective date of termination.  Upon expiration of this Agreement, Company shall pay to Hospital the royalties set forth in Section 4.5(a) for post-termination Sales pursuant to this Section 10.9 of any Product or Process that was in inventory or was a work-in-progress on the date of termination of this Agreement.
11.      COMPLIANCE WITH LAW
11.1    Compliance.  Company shall have the sole obligation for compliance with, and shall ensure that any Affiliates and Sublicensees comply with, all government statutes and regulations that relate to Products and Processes, including, but not limited to, those of the Food and Drug Administration and the Export Administration, as amended, and any applicable laws and regulations of any other country in the License Territory.  Company agrees that it shall be solely responsible for obtaining any necessary licenses to export, re-export, or import Products or Processes covered by Patent Rights and/or Confidential Information.  Company shall indemnify and hold harmless Hospital and Harvard for any breach of Company's obligations under this Section 11.1.
11.2    Patent Numbers.  Company shall cause all Products sold in the United States to be marked with all applicable U.S. Patent Numbers, to the extent required by United States law.  Company shall similarly cause all Products shipped to or sold in any other country to be marked in such a manner as to conform with the patent laws and practices of such country.
12.      MISCELLANEOUS

Page 31 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

12.1    Entire Agreement.  This Agreement constitutes the entire understanding between the Parties with respect to the subject matter hereof. The Parties hereby acknowledge and agree that each of the Original Agreement and the Binding Term Sheet is hereby amended and restated in its entirety and, as of the Restated Effective Date, in its entirety superseded in all respects by this Agreement.
12.2    Notices.  Any notices, reports, waivers, correspondences or other communications required under or pertaining to this Agreement shall be in writing and shall be delivered by hand, or sent by a reputable overnight mail service (e.g., Federal Express), or by first class mail (certified or registered), or by facsimile confirmed by one of the foregoing methods, to the other Party.  Notices will be deemed effective (a) three (3) working days after deposit, postage prepaid, if mailed, (b) the next day if sent by overnight mail, or (c) the same day if sent by facsimile and confirmed as set forth above or delivered by hand.  Unless changed in writing in accordance with this Section, the notice address for Hospital shall be as follows:
Director, Innovation   
Massachusetts General Hospital 
215 First Street, Suite 500   
Cambridge, MA 02142 

Unless changed in writing in accordance with this Section, the notice address for Harvard shall be as follows:
Chief Technology Development Officer
Harvard Office of Technology Development
1350 Massachusetts Avenue Holyoke Center, Suite 727E Cambridge, MA 02138
Fax No. (617) 495-9568

Unless changed in writing in accordance with this Section, the notice address for Company shall be as follows:
OvaScience, Inc.
9 Fourth Avenue
Waltham, MA 02451
Attn: Chief Legal Officer
12.3    Amendment; Waiver.  This Agreement may be amended and any of its terms or conditions may be waived only by a written instrument executed by an authorized signatory of the Parties or, in the case of a waiver, by the Party waiving compliance.  The failure of either 

Page 32 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Party at any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same.  No waiver by either Party of any condition or term shall be deemed as a further or continuing waiver of such condition or term or of any other condition or term.
12.4    Binding Effect.  This Agreement shall be binding upon and inure to the benefit of and be enforceable by the Parties hereto and their respective permitted successors and assigns.
12.5    Assignment.  Company shall not assign this Agreement or any of its rights or obligations under this Agreement without the prior written consent of Hospital; provided, however, that no such consent will be required to assign this Agreement to an Affiliate of Company, to a successor to all or substantially all of the Company’s business to which this Agreement pertains or to a purchaser of all or substantially all of the Company’s assets related to this Agreement, so long as such Affiliate, successor or purchaser shall agree in writing to be bound by all of the terms and conditions hereof prior to such assignment.  Company shall notify Hospital in writing of any such assignment and provide a copy of all assignment documents and related agreements to Hospital within [***] days of such assignment.  Failure of an assignee to agree to be bound by the terms hereof or failure of Company to notify Hospital and provide copies of assignment documentation shall, if not cured as permitted by Section 10.4, be grounds for termination of this Agreement for default.
12.6    Force Majeure.  Neither Party shall be responsible for delays resulting from causes beyond the reasonable control of such Party, including without limitation fire, explosion, flood, war, sabotage, strike or riot, infectious disease outbreak, civil commotion, lockouts, or other labor disturbances, or acts of terrorism (each, a “Force Majeure”), provided, that, the nonperforming Party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and reasonably re-commences its performance under this Agreement whenever such causes are removed.
12.7    Use of Name.  Neither Party shall use the name of the other Party or Harvard or of any its Affiliates and their respective current or former trustees, directors, officers, medical and professional staff, governing board members, faculty, students, employees, and agents of the other Party or any adaptation thereof in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the Party or individual whose name is to be used. For Hospital, such approval shall be obtained from Hospital's VP of Public Affairs. Notwithstanding the forgoing, this shall not prohibit Company from stating the factual existence of this Agreement and its Terms.
12.8    Governing Law.  This Agreement shall be governed by and construed and interpreted in accordance with the laws of the Commonwealth of Massachusetts, excluding with respect to conflict of laws, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted.  Each Party agrees to submit to the exclusive jurisdiction of the Superior Court for Suffolk County, Massachusetts, and the United States District Court for the District of Massachusetts with respect to any claim, suit or action in law or equity arising in any way out of this Agreement or the subject matter hereof.

Page 33 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

12.9    Board Observer.  Hospital shall be entitled to have one representative of Hospital (the “Hospital Observer”) attend all regularly held and special meetings of the Board of Directors of Company (the “Board”) in a nonvoting observer capacity and to receive notice of all meetings of the Board, and Company shall give such Hospital Observer copies of all notices, minutes, consents and other material that it provides to its directors at or about the same time as delivered to such directors; provided, however, that: (a) Company reserves the right to exclude the Hospital Observer from any meeting or portion thereof of the Board or from access to any material or portion thereof if Company reasonably believes that such exclusion or withholding of information with respect thereto is reasonably necessary (i) to preserve attorney-client privilege, (ii) in the event the Board intends to discuss or vote upon any circumstances or matters where there is a material actual or material potential conflict of interest between Company and Hospital, including without limitation any discussion of the Parties’ rights and obligations under this Agreement, or (iii) to comply with the terms and conditions of confidentiality agreements with third parties; (b) the Hospital Observer shall be an Executive Director, Director, or Sr. Business Strategy & Licensing Manager from Hospital’s Innovation Office; the identity of the Hospital Observer shall be subject to the approval of Company’s Board, which approval shall not to be unreasonably withheld or delayed; and (c) the Hospital, on behalf of Hospital Observer, shall enter into a confidentiality agreement with Company in form and substance reasonably satisfactory to Company requiring the Hospital and Hospital Observer to maintain the confidentiality of Company information disclosed to the Hospital Observer.  Hospital’s right under this Section 12.9 shall expire upon the earlier of (A) the closing of the initial public offering of Company’s capital stock, (B) a Change of Control or (C) if the investors in a Series B preferred stock sale (or a subsequent round ) by the Company object to the continuation of the Hospital Observer, the initial closing of such Series B preferred stock sale, provided the Parties shall agree on alternative arrangements to keep Hospital informed of the activities of the Company above the current reporting requirements.
12.10    Hospital Policies.  Company acknowledges that Hospital’s employees and medical and professional staff members and the employees and staff members of Hospital’s Affiliates are subject to the applicable policies of Hospital and such Affiliates, including, without limitation, policies regarding conflicts of interest, intellectual property and other matters.  Company shall provide Hospital with any agreement it proposes to enter into with any employee or staff member of Hospital or any of Hospital’s Affiliates relating to the subject matter of this Agreement for Hospital’s prior review and shall not enter into any oral or written agreement with such employee or staff member which conflicts with any such policy.  Hospital shall provide Company, at Company’s request, with copies of any such policies applicable to any such employee or staff member.
12.11    Severability.  If any provision(s) of this Agreement are or become invalid, are ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the term hereof, it is the intention of the Parties that the remainder of this Agreement shall not be affected thereby.  It is further the intention of the Parties that in lieu of each such provision which is invalid, illegal or unenforceable, there be substituted or added as part of this Agreement a provision which shall be as similar as possible in 

Page 34 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

economic and business objectives as intended by the Parties to such invalid, illegal or enforceable provision, but shall be valid, legal and enforceable.
12.12    Survival.  In addition to any specific survival references in this Agreement, Sections 1, 2.3, 4.2, 4.7, 4.8, 5.3, 5.4, 5.5, 6.4, 7 (with respect to any patent infringement action initiated by Company prior to termination of this Agreement), 8.1, 8.2, 9.2, 9.3, 10.7, 10.8, 10.9, 12.1, 12.2, 12.3, 12.4, 12.6, 12.7, 12.8, 12.10, 12.11, 12.12, 12.13, 12.14, and 12.15 shall survive termination or expiration of this Agreement.  Any other rights, responsibilities, obligations, covenants and warranties which by their nature should survive this Agreement shall similarly survive and remain in effect.
12.13    Interpretation.  The Parties hereto are sophisticated, have had the opportunity to consult legal counsel with respect to this transaction and hereby waive any presumptions of any statutory or common law rule relating to the interpretation of contracts against the drafter.
12.14    Headings.  All headings are for convenience only and shall not affect the meaning of any provision of this Agreement.
12.15    Full Compliance as of Restated Effective Date. The Parties hereby agree that each Party is in full compliance with the terms of this Agreement as of the Restated Effective Date. Without limiting the foregoing, Hospital hereby agrees that Company as of the Restated Effective Date has fully satisfied the following sections: 3.1(a)(i)-(v); 3.1(a)(vii); 3.1(a)(viii)(A)-(E); 3.1(b)(i)(A); 3.1(b)(i)(B); 4.1(a); 4.1(b); 4.4(a)(ii); and has been fully compliant with sections: 3.1(c)(iii); 3.3; 4.2; 4.3(a)-(c); 4.5(a); 4.5(d)(i); 4.5(d)(ii)(A); 4.6; 6.1; 8.2(A); and 12.9. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as of the Restated Effective Date first written above.
	
		
	OVASCIENCE, INC.

BY: /s/ Christopher Kroeger   
   Name:  

TITLE:  CEO   

DATE:  12/7/17   

	THE GENERAL HOSPITAL CORPORATION, D/B/A MASSACHUSETTS GENERAL HOSPITAL

BY: /s/  Emy Chen   
   Name:  Emy Chen

TITLE:  Associate Director   

DATE:  November 6, 2017   

Page 35 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Appendix A
BINDING TERM SHEET 

The Binding Term Sheet, dated as of August 29, 2016 and executed by both Hospital and Company, appears on the four pages that immediately follow this page.

[Remainder of page intentionally left blank]

Page 36 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

BINDING TERM SHEET
August 29, 2016
Nina Green
Partners HealthCare Innovation 215 First Street, Suite 500
Cambridge, MA 02142 Dear Nina,
1.This binding term sheet (this “Term Sheet”), dated 29 August 2016 (the “BTS Date”) is entered into as a legally binding contract between OvaScience, Inc., a Delaware corporation with offices at Nine 4th Avenue in Waltham, MA 02451 (“OvaScience”), and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation with offices at 55 Fruit Street in Boston, MA 02114 (“Hospital”) (each of OvaScience and Hospital referred to herein individually as a “Party”, and collectively as the “Parties”).

2.OvaScience and Hospital previously entered into an exclusive license agreement related to, inter alia, Hospital’s rights to egg precursor cell technology, dated June 27, 2011 , which license agreement was subsequently amended by the Parties in amendments dated September 7 2011, July 30 2013, September 9 2013, November 14 2013, and December 18 2013 (as so amended, the “Agreement”).

3.In the interest of eliminating ambiguities and any misalignment that might exist between the Parties on account of the Agreement, and to promote optimal alignment between the Parties moving forward, the Parties hereby agree to further amend the Agreement to reflect the modified rights and obligations provided in Schedule A to this Term Sheet (the “Amended Terms”); provided, however, that the effectiveness of such Amended Terms is expressly conditioned upon, and subject to, the approval of OvaScience’s Board of Directors at a meeting of the Board, which is scheduled to occur on September 7, 2016.

4.In the event that OvaScience’s Board of Directors approves the Amended Terms, (1) the Agreement shall be deemed to have been amended in accordance with the Amended Terms immediately effective upon the delivery by OvaScience to Hospital of written notice of such Board of Directors’ approval, (2) any amounts that are payable by OvaScience upon execution and/or signing of the amended and restated license agreement incorporating the Amended Terms will be payable by OvaScience within ten (10) business days of the date of such written notice (or, if the amended and restated license is not executed by the Parties and an amount is payable by OvaScience upon a specified anniversary, within ten (10) business days of the anniversary of the date of such written notice), and (3) the Parties will undertake to negotiate and execute in good faith an amended and restated license agreement that incorporates the substance of the Agreement as further amended by the Amended Terms, it being expressly understood

Page 37 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

BINDING TERM SHEET

that no such amended and restated license agreement is required in order to make the Amended Terms set forth in this Term Sheet effective.
5.The existence and the terms of this Term Sheet, and any information exchanged in furtherance of generating this Term Sheet and/or in preparing and executing the amended and restated license agreement, shall be confidential information of OvaScience. Hospital agrees to hold in confidence and not use, disclose or reveal to any other person any such information unless and until such information has become generally available to the public through no fault or omission on the part of Hospital.
6.The Parties have entered into this Term Sheet on the BTS Date. This Term Sheet is intended to be a valid and binding agreement, enforceable against the Parties and their respective successors and assigns, whether or not the Parties enter into the amended and restated license agreement, subject only to the approval of OvaScience’s Board of Directors. Any capitalized but undefined terms in this Term Sheet or Schedule A hereto shall have the meanings ascribed to them in the Agreement; additionally, “CRE” shall mean commercially reasonable efforts and shall include considerations of strategy, as well as the presence or absence of (i) intellectual property protection, and (ii) regulatory requirements or concerns. The validity, interpretation and performance of this Term Sheet is controlled by and construed under the laws of the Commonwealth of Massachusetts, without giving effect to the principles of conflicts of law thereof. The Parties acknowledge and agree that (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Term Sheet and have contributed to its revision, and (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party will not be employed in the interpretation of this Term Sheet. This Term Sheet may be executed by facsimile and in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one agreement binding on both Parties.

OvaScience, Inc.    The General Hospital Corporation (d/b/a     “Massachusetts General Hospital”)

/s/ Harald Stock                    /s/ Sepideh Hashemi            
By: Harald Stock                    By: Sepideh Hashemi
Title: President and CEO                Title: Market Sector Leader 

9/6/16                        9/6/2016                    
Date                        Date

Page 38 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Schedule A
Schedule of Amended Terms to Exclusive License Agreement	
					
	Issue
	Agreed Upon Provisions (Subject to approval by OvaScience’s Board of Directors)

	Consolidation of fields
	Merge 3 fields (License, Expanded, JV) into 1 unified “all fields” field

	Economic considerations stemming from field consolidation
	Aggregate annual payments of $[***] for unified field.

	Add two milestones by which OvaScience pays $[***] upon the FCS for both treating menopause, and for diagnostics.

	Royalty on Net Sales. MGH proposes to keep the royalty on Net Sales separate with [***]% for human, and [***]% for animal, applications.

Solely with respect to the Media Patent Rights, and in consideration for the [***] extension of FCS obligations by Harvard, OvaScience agrees that it will continue to pay royalties on Net Sales within the Limited Field (i.e., the “[***] Media Patent Rights” field) at [***]% of the rates above for [***] years ([***] months) following the expiration of the Media Patent Rights, provided that the following two conditions are met before any such extension comes into force or effect:
(1)    a patent within the Media Patent Rights becomes granted and enforceable in the country where the Net Sales are being generated; and
(2)    such patent directly covers the Product or Process on which such Net Sales are assessed.

	a.   Further Reductions in Rate.

	i.   Combination Product Provision.  An additional formula of C/D for determining the amount of Net Sales attributable to a Combination Product where D is the average selling price of the combination product sold in a given market and C is the average selling price of the isolated royalty-bearing product or process in that market (e.g., where we sell an EggPC-derived egg or embryo in a market such as animal husbandry, wherein the embryo doesn’t utilize any proprietary technology of another, which egg/standard embryo would be the royalty-bearing product/process and the ultimate cow generated the combination product). This formula would not displace the other formulas provided, but would supplement those formulas.

	ii.   Royalty Floor.   The overall floor on the royalty rate shall be [***]% if OvaScience exercises both Stacking Provisions and Combination Product Provisions for a single product. The Royalty Floor shall remain at [***]% in the event that either the Stacking OR Combination Provisions are invoked by OvaScience.

	2. Royalty on Sublicense Income. MGH would like to recognize OvaScience’s contribution towards development of commercially valuable technology by an appropriately reducing/stepping down amount of Sublicense Income due for the combined fields which is directly attributable to the sublicense grant as follows:

	 
	As of Date
	% Sublicense Income
	 

	Effective Date of License (“ED”)
	[***]%
	 

	3rd  Anniversary ED
	[***]%
	 

Page 39 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

	
					
	 
	 
	5th Anniversary ED
	[***]%, provided that OVAS pays MGH
$100K upon execution of the restatement.
	 

	7th  Anniversary of ED
	[***]%, provided that OVAS pays MGH additional $[***] by the first anniversary of the restatement’s execution.
	 

	Claw-Back Provisions
	3.   Realigning Diligence Obligations.

	a.   Elimination of Clinical POC Obligation.  Eliminate clinical POC study, and OvaScience will pay the $[***] milestone for achieving clinical POC within [***] of execution of the restatement.

	b.   Extending Timing of First Commercial Sale (“FCS”). Extend the FCS from [***] for EggPC platform in any required geographies.

	c.    Restructuring Nature of Required Geographies.
i.    Change to CRE re: specific big pharma targets to regional markets (e.g., 1 country in North America, 1 Central or South American country, 1 country in the Middle East, 2 countries in Asia Pacific, and 2 countries within or candidates for the EU) within [***] of Effective Date; and
ii.    OvaScience shall, by the [***] of the restatement’s execution, make FCS in the US

	d.   Extending FCS for [***] Media Patent Rights. OvaScience proposes that we extend the FCS deadline by [***], for which we would pay $[***] upon execution of the
restatement.

	e.   Diligence After FCS: OvaScience proposes that we (a) achieve a FCS in those regions per 3(c), above, and (b) not let any period of [***] or more expire without continued sales in those regions, provided that this period would toll in the event of any actual or threatened regulatory or IP issues. Any failure in achieving the above would be subject to (2), below.

	4.   Providing for Diligence Extensions.  OvaScience can extend any diligence obligation for [***] by paying a $[***] fee; provided, that any diligence obligation could only be so extended [***].

Page 40 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Appendix B
DESCRIPTION OF TECHNOLOGICAL INFORMATION

Page 41 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Appendix C
CONFIDENTIALITY TERMS AND CONDITIONS
1.    Definition of Confidential Information.  “Confidential Information” shall mean any information, including but not limited to data, techniques, protocols or results, or business, financial, commercial or technical information, disclosed by one Party (each a “Discloser” as applicable) to the other Party (each a “Recipient” as applicable) in connection with the terms of that certain Exclusive License Agreement dated _____________________ (the “License Agreement”) and identified as confidential at the time of disclosure (the “Purpose”).  Hospital’s Confidential Information shall also include all information disclosed by Hospital to Company in connection with the Patent Rights.  Capitalized terms used in this Appendix that are not otherwise defined herein have the meanings ascribed in the License Agreement to which this Appendix is attached and made a part thereof.
2.    Exclusions.  “Confidential Information” under this Agreement shall not include any information that (i) is or becomes publicly available through no wrongful act of Recipient; was known by Recipient prior to disclosure by Discloser, as evidenced by tangible records; (iii) becomes known to Recipient after disclosure from a third party having an apparent bona fide right to disclose it; (iv) is independently developed or discovered by Recipient without use of Discloser’s Confidential Information, as evidenced by tangible records; or (v) is disclosed to another party by Discloser without restriction on further disclosure.  The obligations of confidentiality and non-use set forth in this Agreement shall not apply with respect to any information that Recipient is required to disclose or produce pursuant to applicable law, court order or other valid legal process provided that Recipient promptly notifies Discloser prior to such required disclosure, discloses such information only to the extent so required and cooperates reasonably with Discloser’s efforts to contest or limit the scope of such disclosure.
3.    Permitted Purpose.  Recipient shall have the right to, and agrees that it will, use Discloser’s Confidential Information solely for the Purpose (as defined above), except as may be otherwise specified in a separate definitive written agreement negotiated and executed between the Parties.
4.    Restrictions.  For the term of the License Agreement and a period of [***] years thereafter (and indefinitely with respect to any individually identifiable health information disclosed by Hospital to Company, if any), each Recipient agrees that: (i) it will not use such Confidential Information for any purpose other than as specified herein, including without limitation for its own benefit or the benefit of any other person or entity; and (ii) it will use reasonable efforts (but no less than the efforts used to protect its own confidential and/or proprietary information of a similar nature) not to disclose such Confidential Information to any other person or entity except as expressly permitted hereunder.  Recipient may, however, disclose Discloser’s Confidential Information only on a need-to-know basis to its and its Affiliates employees, staff members and agents (“Receiving Individuals”) who are directly participating in the Purpose and who are informed of the confidential nature of such information, provided Recipient shall be responsible for compliance by Receiving Individuals with the terms of this Agreement and any breach thereof.  In addition, (a) Company 

Page 42 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

may use and disclose Confidential Information of Hospital in accordance with the License Agreement as reasonably required for development, regulatory, manufacturing and commercialization activities with respect to Products and Processes, (b) Company may further make such disclosures as Company reasonably determines are required under applicable law or regulation, including without limitation applicable securities laws and regulations and the rules or regulations of any applicable securities exchange or Nasdaq, and (c) Company may make such disclosures of Confidential Information to Company’s and its Affiliates’ actual or potential directors, investors, funding sources, acquirers and licensees, provided that such recipient is bound to keep such information confidential substantially as provided herein.  Each Party further agrees not to use the name of the other Party or any of its Affiliates or any of their respective trustees, directors, officers, staff members, employees, students or agents in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the Party or individual whose name is to be used, in the case of Hospital such approval to be given by the Public Affairs Department.  This Section 4 shall survive termination or expiration of this Agreement.
5.    Right to Disclose.  Discloser represents that to the best of its knowledge it has the right to disclose to each Recipient all of Discloser’s Confidential Information that will be disclosed hereunder.
6.    Ownership.  All Confidential Information disclosed pursuant to this Agreement, including without limitation all written and tangible forms thereof, shall be and remain the property of the Discloser.  Upon termination of this Agreement, if requested by Discloser, Recipient shall return or destroy at Discloser’s discretion all of Discloser’s Confidential Information, provided that Recipient shall be entitled to keep one copy of such Confidential Information in a secure location solely for the purpose of determining Recipient’s legal obligations hereunder or of exercising any rights of Recipient which survive such termination.
7.    No License.  Nothing in this Agreement shall be construed as granting or conferring, expressly or impliedly, any rights by license or otherwise, under any patent, copyright, or other intellectual property rights owned or controlled by Discloser relating to Confidential Information, except as specifically set forth in the License Agreement.
8.    Remedies.  Each Party acknowledges that any breach of this Agreement by it may cause irreparable harm to the other party and that each party is entitled to seek injunctive relief and any other remedy available at law or in equity.
9.    General.  These Confidentiality Terms and Conditions, along with the License Agreement, contain the entire understanding of the parties with respect to the subject matter hereof, and supersede any prior oral or written understandings between the parties relating to confidential treatment of information.  Sections 1, 2, 4, 6, 8 and 9 of these Confidentiality Terms and Conditions shall survive any expiration or termination of the License Agreement.

Page 43 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Appendix D
HOSPITAL AND AFFILIATES 
MASSACHUSETTS GENERAL HOSPITAL  
BRIGHAM AND WOMEN’S HOSPITAL  
NEWTON-WELLESLEY HOSPITAL 

Page 44 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Appendix E
SALES REPORTS
AGREEMENT INCOME REPORT    Royalty Income 
[MGH][BWH] Agreement #-        
Licensee -        
Sub-Licensee -        

Separate reports must be filed for:
1.    Each Product sold.
2.    Each country of sale, if different deductions or royalty rates apply.

Product Name:         
Report Time Period:
From     mm/dd/yyyy         
To     mm/dd/yyyy         

	
	
	 

Country of Sale                         
Quantity Sold                         
Gross Sales (USD)     $        $        $    
Exchange Rate                         
Deductions (Itemize)
Please list each deduction separately.  Use same definition as appears in Agreement and include the contract paragraph as a reference (Std Section 1.17(a)(ii) line item deductions listed below).

A1.                        
A2.                        
A3.                        
A4.                        
B.                        

Total Deductions    (    )    (    )     (    )
Net Sales                        
Royalty Percentage                         
Credits (itemize)    (    )    (    )    (    )

Page 45 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Royalties Due    $         $         $    

Page 46 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED

Appendix F
AGREEMENT INCOME REPORT    Sublicense Income 

[MGH][BWH] Agreement #-        
Licensee -        
Sub-Licensee -        

Separate reports must be filed for Payments associated with each Product:
Product Name:         
Report Time Period:
From    mm/dd/yyyy         
To    mm/dd/yyyy         

	
	
	 

Detailed Explanation of Payment
Required for “Other Payment”

Annual Fees/Minimum Royalties    $            
Milestone Payments    $            
Sublicense Fees and Royalties    $            
Other Payment    $            
Other Payment    $            
Other Payment    $            
TOTAL    $    

	
	
	 

PLEASE ATTACH DETAIL AS REQUIRED

Page 47 of 45
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Exhibit

Exhibit 10.36

December 21, 2017

James Lillie
13 Forest Street
Wellesley, MA 02481

Dear James,

On behalf of OvaScience, Inc. (the “Company”), I am pleased to offer you employment with the Company.  The purpose of this letter and the documents referenced below is to summarize the terms of your employment with the Company, should you accept our offer.    

1.    Employment.  You will be employed pursuant to the terms of this letter agreement on January 15, 2018, to serve on a full-time basis as Chief Scientific Officer at OvaScience.  In this role, you will report to the Chief Executive Officer of OvaScience and will have such duties and responsibilities as are customary for such position and as are otherwise assigned to you from time to time by the Company.  You agree to devote your full business time, best efforts, skill, knowledge, attention and energies to the advancement of the Company’s business and interests and to the performance of your duties and responsibilities as an employee of the Company, and not to engage in any other business activities without the Company’s prior approval. 

2.    Compensation.  Your base salary rate will be $13,846.16 per bi-weekly pay period, equivalent to $360,000.16 on an annualized basis, subject to tax and other withholdings as required by law, to be paid in installments in accordance with the Company’s standard payroll practices. Such salary may be adjusted from time to time in accordance with normal business practice and in the sole discretion of the Board.  In addition to your base salary, you will be eligible to receive an annual discretionary bonus award of up to forty percent (40%) of your eligible calendar year base salary earnings.  The bonus award, if any, will be determined by the Board of Directors of the Company or a Committee thereof (the “Board”) in its sole discretion, based on achieving specific goals to be determined by the Chief Executive Officer of the Company in consultation with the Board.   You must be an active employee of the Company on the date on which bonuses are distributed to receive and to be deemed as having earned any bonus award.  

3.    Benefits.  You will be eligible to participate in any and all benefit programs that the Company establishes and makes available to its employees from time to time, provided you meet the specific eligibility criteria as set forth in (and subject to all provisions of) the plan documents governing those programs.  The benefits made available by the Company, and the rules, terms and conditions for participation in such benefit plans, may be changed by the Company at any time and from time to time without advance notice.        
4.    Vacation.  You may be eligible for a maximum of 20 days of vacation per calendar year, subject to proration to your date of hire and to be taken at such times as may be approved by the Company. The number 

                    

of vacation days for which you are eligible shall accrue at the rate of 6.15 hours per pay period that you are employed during such calendar year.  

5.    Reimbursement of Business Expenses.  During the execution of your duties in this position, you may from time to time incur expenses. Upon presentation of appropriate documentation itemizing such expenditures and attaching all supporting vouchers and receipts, you shall be reimbursed for all reasonable and necessary business and entertainment expenses incurred in connection with the performance of your duties in accordance with the Company’s expense reimbursement practice.
 
6.    Equity.  On the start date, subject to the approval of the Board (including a majority of the independent members of the Board) or Compensation Committee, the Company will grant to you a non-qualified stock option (the “Option”) for the purchase of an aggregate of 357,057 shares of Common Stock of the Company (subject to appropriate adjustments for stock splits, stock dividends, combinations, recapitalizations and similar transactions affecting the Common Stock of the Company after the date hereof) at a price per share equal to the closing sale price of the Common Stock on the Nasdaq Global Market on the date of grant, as an inducement material to you joining the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listed Company Manual.  The Option shall be subject to all terms, vesting schedules and other provisions set forth in a separate option agreement. The Option will have a term of ten (10) years except as set forth in the stock option agreement and be subject to a vesting schedule of four (4) years, with 25% of the shares vesting on the first anniversary of your employment start date and 6.25% of the shares vesting each quarter thereafter. You may be eligible to receive future stock options grants as the Board shall deem appropriate and in its sole and absolute discretion.
Notwithstanding anything to the contrary in the stock option agreement, if a “Change in Control Event” (as defined on Exhibit A attached hereto) occurs and, within one (1) year of such Change in Control Event, your employment is terminated by the Company (or any successor) without “Cause” (as defined on Exhibit A) or by you for “Good Reason” (as defined on Exhibit A), the vesting schedule of the Option shall be accelerated in full.
7.    Severance Benefits Upon Termination by the Company Without “Cause” or by you for “Good Reason”.  If the Company terminates your employment without Cause (as defined on Exhibit A attached hereto) or you terminate your employment for Good Reason (as defined on Exhibit A), you shall be eligible to receive the following severance benefits: (a) severance pay in an amount equal to six (6) months of your base salary as in effect at the time of your termination, payable in accordance with the Company’s regular payroll procedures proportionately over a six (6) month period following the termination of your employment (such period, the “Severance Period”), (b) should you be eligible for and elect to continue receiving group medical and dental insurance coverage under the law known as COBRA, the Company shall continue to pay on your behalf that portion of the monthly premiums for such coverage that it pays for active and similarly situated employees receiving the same type of coverage, through the earlier of (x) the last day of the Severance Period, or (y) the date that you become eligible for group health and/or dental insurance coverage from any new employer.  No severance pay or other benefit hereunder shall be provided to you unless, within sixty (60) days following the date that your employment is terminated, you first execute and do not revoke a separation agreement in a form prepared by and acceptable to the Company, which shall include, at a minimum, a full release of all claims against the Company (as well as its parents, subsidiaries and affiliates, and its and their, executives, officers, directors, employees, consultants, agents, shareholders, and assigns), as well as non-disparagement and confidentiality provisions in favor of the Company (the “Separation Agreement”).   The severance payments shall commence on the first payroll period following the date the Separation Agreement becomes effective (the “Payment Date”).  Notwithstanding the payment requirements set forth 

                    

in the immediately preceding sentence, if the sixty (60) day period following the date your separation from service begins in one tax year and ends in the following tax year, the Company will commence payment on the next regular payroll date following the later of January 1 of the second tax year and the date the Separation Agreement becomes enforceable and no longer subject to revocation.  The first such payment will include a catch-up payment equal to all amounts you otherwise would have received under Section 6(a) prior to the first payment.  The distribution of any severance payments shall be subject to the provisions of Exhibit B attached hereto.  

8.    Notices.  Any purported termination of employment by the Company for Cause or by you for Good Reason shall be communicated to the other party through written notice, indicating the specific grounds for such termination.  Such notice, and all other communications which are required or many be given pursuant to the terms of this letter, shall be sufficient in all respects if given in writing and shall be deemed given if (a) if delivered personally, on the date of delivery, (b) if mailed by certified or registered mail, return receipt requested and postage prepaid, three (3) days after the mailing date, (c) if sent via a nationally recognized overnight courier, on the next business day thereafter, or (d) if sent via facsimile confirmed in writing to the recipient, or via email, on the next business day thereafter, in each case, if to the Company, at the Company’s principal place of business, and if to you at the most recent home address (and/or, as applicable, the most recent personal email address) which you have provided to the Company or to such other address or addresses as either party shall have designated in writing to the other party.  

9.    Inventions, Confidentiality, Non-Competition and Non-Solicitation.  As a condition of your employment with the Company, you will be required to execute an Invention and Non-Disclosure Agreement and a Non-Competition and Non-Solicitation Agreement in the forms attached as Exhibit C and Exhibit D.

10.    Other Agreements and Governing Law; Jury Trial Waiver.  You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.  Please note that this offer letter is your formal offer of employment and supersedes any and all prior or contemporaneous agreements, discussions and understandings, whether written or oral, relating to the subject matter of this letter or your employment with the Company.  The resolution of any disputes under this letter will be governed by Massachusetts law.  Both the Company and you expressly waive any right that either party has or may have to a jury trial with respect to any dispute arising out of or in any way related to your employment with and/or termination of employment from the Company. 

11.    Background Verification and Proof of Legal Right to Work.  This offer of employment is contingent upon your successful completion of a pre-employment background verification.  You will be contacted by the Company’s background verification vendor to provide information necessary to perform the background verification following your acceptance of this offer.  In addition, you will be required to provide the Company, within three days following your hire date, documentation of your identity and eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986. 

12.    Company Policies and Procedures.  As an employee of the Company, you will be required to comply with all Company policies and procedures, including its Code of Business Conduct.  Violations of the Company’s policies may lead to immediate termination of your employment.  Further, the Company’s premises, including all workspaces, furniture, documents and other tangible materials, and all information technology resources of the Company (including computers, data and other electronic files, and all internet and email) are subject to oversight and inspection by the Company at any time.  Company employees should 

                    

have no expectation of privacy with regard to any Company premises, materials, resources or information.      

13.    At-Will Employment.  This letter shall not be construed as an agreement, either expressed or implied, to employ you for any stated term, and shall in no way alter the Company’s policy of employment at will, under which both you and the Company remain free to terminate the employment relationship, with or without cause, at any time, for any reason or no reason, with or without notice. Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company, except as otherwise explicitly stated herein.

If you agree with the provisions of this letter, please sign this letter in the space provided below and return it to Katharine Mathews in Human Resources.   I am confident that you will make a great addition to the OvaScience team and I look forward to working together.   

Very truly yours,

OVASCIENCE, INC.

By: ___________________________
Christopher Kroeger, Chief Executive Officer

The foregoing correctly sets forth the terms of my at-will employment by OvaScience, Inc.

Name: ______________________________            Date: ______________________
James Lillie

                    

Exhibit A
Definitions
“Cause” for termination shall be deemed to exist upon:
		
	(a)
	a good faith finding by the Company (i) of failure of or refusal of the employee to perform his or her duties and responsibilities to the Company, or (ii) that the employee has engaged in dishonesty, gross negligence or misconduct, which dishonesty, gross negligence or misconduct has caused harm or damage the business, affairs or reputation of the Company;

		
	(b)
	the commission by the employee of, the conviction of the employee of, or the entry of a pleading of guilty or nolo contendere by the employee to, any crime involving moral turpitude or any felony; or

		
	(c)
	a breach by the employee of any material provision of any invention and non-disclosure agreement or non-competition and non-solicitation agreement with the Company, which breach is not cured within ten (10) days’ written notice thereof.

A “Change in Control Event” shall be deemed to exist upon the sale of all or substantially all of the outstanding share of capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a transaction in which all or substantially all of the individuals and entities who were beneficial owners of the capital stock of the Company immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities (on an as-converted to Common Stock basis) entitled to vote generally in the election of directors of the (i) resulting, surviving or acquiring corporation in such transaction in the case of a merger, consolidation or sale of outstanding shares, or (ii) acquiring corporation in the case of a sale of assets); provided that, in each of the foregoing cases, the Change in Control Event also meets all of the requirements of a “change in ownership of a corporation” within the meaning of Treasury Regulation §1.409A-3(i)(5)(v) or a “change in the ownership of a substantial portion of the corporation’s assets” within the meaning of Treasury Regulation §1.409A-3(i)(5)(vii).
“Good Reason” shall be deemed to exist upon:
		
	(a)
	the relocation of the Company’s offices such that the employee’s daily commute is increase by at least 30 miles each way without the written consent of the employee;

		
	(b)
	material reduction of the employee’s annual base salary without the prior consent of the employee (other than in connection with, and substantially proportionate to, reductions by the Company of the annual base salary of more than 50% of its employees); or

		
	(c)
	material diminution in employee’s duties, authority or responsibilities without the prior consent of the employee, other than changes in duties, authority or responsibilities resulting from the employee’s misconduct;

provided, however, that no such event or condition shall constitute Good Reason unless (x) the employee gives the Company a written notice of termination for Good Reason not more than 90 days after the initial existence of the condition, (y) the grounds for termination if susceptible to correction are not corrected by the Company within 30 days of its receipt of such notice and (z) the employee’s termination of employment occurs within six months following the Company’s receipt of such notice.

                    

Exhibit B
Payments Subject to Section 409A
1.Subject to this Exhibit B, payments or benefits during the Severance Period under this offer letter (“Severance Payments”) shall begin only upon the date of your “separation from service” (determined as set forth below) which occurs on or after the termination of your employment.  The following rules shall apply with respect to distribution of Severance Payments, as applicable:
		
	(a)
	It is intended that each installment of the Severance Payments shall be treated as a separate “payment” for purposes of Section 409A of the Code and the guidance issued thereunder (“Section 409A”).  Neither the Company nor you shall have the right to accelerate or defer the delivery of any such Severance Payments except to the extent specifically permitted or required by Section 409A.

		
	(b)
	If, as of the date of your “separation from service” from the Company, you are not a “specified employee” (within the meaning of Section 409A), then each installment of the Severance Payments shall be made on the dates and terms set forth in the offer letter.

		
	(c)
	If, as of the date of your “separation from service” from the Company, you are a “specified employee” (within the meaning of Section 409A), then:

		
	(i)
	Each installment of the Severance Payments due under the offer letter than, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when your separation from service occurs, be paid within the Short-Term Deferral Period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and shall be made on the dates and terms set forth in the offer letter; and

		
	(ii)
	Each installment of the Severance Payments due under the offer letter that is not described in this Exhibit B, Section 1(c)(i) and that would, absent this subsection, be paid within the six-month period following your “separation from service” from the Company shall not be paid until the date this is six months and one day after such separation from service (or, if earlier, your death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one date following your separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of Severance Payments if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).  Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(iii) must be paid no later than the last day of your second taxable year following the taxable year in which the separation from service occurs.

                    

2.The determination of whether and when your separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h).  Solely for purposes of this Exhibit B, Section 2, “Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.
3.All expense reimbursements shall be paid as soon as administratively practicable.  If an expense reimbursement or provision of in-kind benefits is not exempt from Section 409A of the Code, the following rules apply: (a) in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred; (b) the amount of reimbursable expenses incurred or provision of in-kind benefits in one tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind benefits in any other tax year; and (c) the right to reimbursement for expenses or provision of in-kind benefits is not subject to liquidation or exchange for any other benefit.
4.The Company makes no representation or warranty and shall have no liability to you or to any other person if any of the provisions of the offer letter (including this Exhibit) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.

                    

Exhibit C
Invention and Non-Disclosure Agreement
This Invention and Non-Disclosure Agreement (“Agreement”) effective on the last date signed below (the “Effective Date”), is between OvaScience, Inc. of Delaware (“OvaScience”) and Employee (“Employee”) (each referred to herein individually as a “Party,” and collectively as the “Parties”).

RECITALS.

Whereas, OvaScience wishes to ensure that its employees (1) maintain the confidentiality of OvaScience’s Proprietary Information (as hereinafter defined), and (2) properly assign all inventions made or conceived while on the job to OvaScience;

Whereas, OvaScience requires, as a condition of employment, that all employees sign a confidentiality and invention agreement; and

Whereas, OvaScience has offered Employee a position with OvaScience, and Employee wishes to accept such offer.

Now, therefore, in consideration of the promises and other terms set forth below, the
Parties agree as follows:

I.    Condition of Employment.   Employee hereby agrees that his/her employment and/or the continuance of that employment with OvaScience is contingent upon his/her agreement to sign and adhere to the provisions of this Agreement.  Employee acknowledges that the protection of Proprietary Information is critical to OvaScience’s survival and success.
II.    Proprietary Information & the Duty of Confidentiality.
A.   Scope of Proprietary Information.  “Proprietary Information” means all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning OvaScience’s business or financial affairs. Without limiting the foregoing, Proprietary Information includes discoveries, inventions, products, product enhancements or improvements, processes, methods, techniques, formulas, compositions, compounds, negotiation strategies and positions, projects, developments, plans (including business and marketing plans), research or clinical data, financial data (including sales costs, profits and pricing methods), personnel data, computer programs (including software used pursuant to a license agreement), customer, prospect and supplier lists, and contacts at or knowledge of customers or prospective customers of OvaScience.

B.    Duty of Confidentiality.   Absent the prior written approval by an officer of OvaScience (“Approval”), Employee shall not, either during or after his/her employment with OvaScience: (1) use Proprietary Information for any purpose other than in the performance of his/her duties as an employee of OvaScience; or (2) disclose any Proprietary Information to any person or entity other than employees of OvaScience.  Employee shall also take reasonable measures to protect against accidental disclosure of Proprietary Information.  Notwithstanding the foregoing, Employee may use or disclose any Proprietary Information to the extent that, as shown through credible evidence, it has become public knowledge without fault by Employee.  While employed by OvaScience, Employee shall use best efforts to prevent unauthorized publication or disclosure of any Proprietary Information.
C.    Ownership & Return of Proprietary Information.  Employee hereby agrees that all Proprietary Information is, and will always be, the exclusive property of OvaScience.  Whether created by Employee or not, Employee also agrees that all tangible or intangible material that comes into his/her custody or possession containing Proprietary Information (including files, documents, letters, memoranda, reports, records, data, sketches, drawings, models, laboratory notebooks, photographs, or computer programs, files, equipment or devices), and any copies or reproductions thereof (collectively, “OvaScience Files”), are, and will always be, the exclusive property of OvaScience.  Upon termination of Employee’s employment, or at any time upon request of OvaScience, Employee shall: (1) promptly deliver all OvaScience Files to OvaScience; and (2) destroy any OvaScience Files that cannot otherwise be returned to OvaScience.
D.    Third Party Information.   Employee agrees that his/her obligations not to use or disclose Proprietary Information, and to return all OvaScience Files, as set forth in Sections II(B)-(C) of this Agreement, also extend to such types of information, materials and tangible property of customers or suppliers of OvaScience, or other third parties who may have disclosed or entrusted the same to OvaScience or Employee in the course of OvaScience’s business.
III.    Disclosure & Assignment of Inventions.
A.      Disclosure of Inventions to OvaScience.   Employee shall make full and prompt disclosure to OvaScience of all discoveries, inventions, improvements, enhancements, processes, methods, techniques, developments, software and works of authorship that she/he solely, or jointly with others, makes, creates, conceives or reduces to practice during his/her employment with OvaScience, whether or not during normal working hours or on the premises of OvaScience (all of which are collectively referred to herein as “Inventions”).
B.    Assignment of Inventions to OvaScience.  Subject only to Section III(C) of this Agreement, and hereby irrevocably assigns, and shall assign, to OvaScience all right, title and interest in and to all Inventions, and all associated patents, copyrights, trademarks, trade names and other industrial and intellectual property rights and applications therefor, in the United States and elsewhere (“IP Rights”). Employee agrees to appoint, and shall appoint, any officer of OvaScience as Employee’s duly authorized attorney to execute, file, prosecute and protect any IP Right before any government agency, court or authority.  Upon OvaScience’s request, and at OvaScience’s expense, Employee shall both during or after his/her employment with OvaScience, execute whatever further assignments, documents, and other instruments as are necessary or desirable to assist OvaScience in applying for, obtaining, and enforcing IP Rights worldwide.  Finally, Employee hereby waives all claims to moral rights in all Inventions; to the extent that applicable law precludes Employee from waiving such moral rights, Employee hereby grants, and shall grant, to OvaScience an exclusive, irrevocable and assignable license under such moral rights for all purposes.
C.    Inventions Not Assignable to OvaScience.   Notwithstanding the provisions of Section III(B) of this Agreement, Employee is not required to assign any Invention which: (1) does not relate to the business or research and development conducted or planned to be conducted by OvaScience when such Invention is created, made, conceived or reduced to practice; and (2) is made and conceived by Employee not during normal working hours, not on OvaScience’s premises, and not using OvaScience’s tools, devices, equipment or Proprietary Information.  Additionally, Employee understands that he is not required to assign any Invention to the extent that such assignment is precluded by state law.
IV.    Legal Compliance.
A.    Other Agreements.  Employee represents that, except as already disclosed in writing to OvaScience, he/she is not bound by the terms of any agreement with any previous employer or other party to refrain from: (1) using or disclosing any trade secret or confidential or proprietary information in the course of his/her employment with OvaScience; (2) competing, directly or indirectly, with the business of such previous employer or other third party; or (3) soliciting employees, customers or suppliers of such previous employer or other third party. Employee further warrants and represents that his/her performance of all the terms of this Agreement and the performance of his/her duties as an employee of OvaScience do not, and will not, conflict with or breach any agreement with, or continuing obligation to, any prior employer or other third party (including any nondisclosure or non-competition agreements).  Finally, Employee warrants that he/she will not disclose to OvaScience or induce OvaScience to use any confidential or proprietary information or material belonging to any previous employer or other third party.
B.    Compliance with OvaScience’s Obligations.  Employee acknowledges that OvaScience may have agreements with other persons or with the U.S. government, or agencies thereof, which impose obligations or restrictions on OvaScience regarding Inventions made during the course of work under such agreements, or regarding the confidential nature of such work.  Employee hereby agrees to be bound by all such obligations and restrictions, and to take all action necessary to discharge the obligations of OvaScience under such agreements.
V.    General Provisions.
A.    Remedies for Breach.  The provisions of this Agreement are necessary for the protection of the business and goodwill of the Parties, and are considered by the Parties to be reasonable for such purpose.  Employee acknowledges and agrees that any breach of this Agreement will cause substantial and irreparable injury to OvaScience; therefore, in the event of a breach and in addition to other remedies which may be available, OvaScience has the right to seek specific performance and other injunctive and equitable relief.
B.    Disclosure of this Agreement. Employee hereby authorizes OvaScience to notify others, including customers of OvaScience and any of Employee’s future employers or prospective business associates, of the terms and existence of this Agreement, and Employee’s continuing obligations to OvaScience hereunder.
C.    Agreement Not an Employment Contract. Employee acknowledges that this Agreement does not constitute a contract of employment, does not imply that OvaScience will continue his/her employment for any period of time, and does not change the at-will nature of his/her employment.
D.    Successors and Assigns.   This Agreement is binding upon, and inures to the benefit of, both Parties and their respective successors and assigns, including any corporation with which, or into which, OvaScience may be merged or which may succeed to its assets or business, provided, however, that the obligations of Employee are personal and therefore Employee may not assign them without Approval.   Employee hereby irrevocably consents to be bound by the provisions of this Agreement for the benefit of OvaScience and any subsidiary or affiliate thereof to whose employ Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.
E.    Severability.  If any provision of this Agreement is illegal or unenforceable, that provision is severed from this Agreement and all other provisions remain in force. If a court of competent jurisdiction deems any provision illegal or unenforceable, the Parties shall undertake to substitute a provision that is as commercially equivalent as possible, in light of the legal interests and intent of this Agreement.
F.    Waivers.  No delay or omission by OvaScience in exercising any right under this Agreement will operate as a waiver of that or any other right.  A waiver or consent given by OvaScience on any one occasion is effective only in that instance, and will not be construed as a bar to, or waiver of, any right on any other occasion.
G.    Choice of Law and Jurisdiction.  The validity, interpretation and performance of this Agreement is controlled by and construed under the laws of the Commonwealth of Massachusetts, without giving effect to the principles of conflicts of law thereof.   The Parties irrevocably submit to the exclusive jurisdiction of the federal and state courts located in Boston, MA.  Each Party hereby irrevocably waives any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding relating to this Agreement in Boston, MA and further irrevocably waives any claim that Boston, MA is not a convenient forum for any such suit, action or proceeding.   Additionally, each Party hereby irrevocably waives any right to a trial by jury in any action, suit or other proceeding arising under or relating to any provision of this Agreement.
H.    Entire Agreement.  This Agreement constitutes the entire agreement among the Parties and supersedes any prior or contemporaneous understanding or agreement with respect to the transaction contemplated hereby.
I.    Modification.  The Parties may only modify this Agreement by a writing signed by both Parties.  Any modifications not made in writing are not effective.
J.    Counterparts.  For the convenience of the Parties, this Agreement can be executed by facsimile and in counterparts, each of which is deemed an original, and both of which taken together constitutes one agreement binding on both Parties.
K.    Construction.  All pronouns and variations thereof refer to masculine, feminine, or neuter genders, singular or plural, as the identity of the person may require. The words “include,” “including” and “includes” as used in this Agreement are deemed to be followed by the words “without limitation.”   This Agreement contains headings only for convenience and the headings do not constitute or form a part of this Agreement, and should not be used in the construction of this Agreement.

The Parties enter into this Agreement on the Effective Date.

OvaScience, Inc.                    Employee

___________________________________                                                                             
Signature                         Signature                     
______________________________________        ______________________________________
Print Name                        Print Name

______________________________________        ______________________________________
Title                            Title

______________________________________        ______________________________________
Date                            Date
Exhibit D
Non-Competition and Non-Solicitation Agreement
This Non-Competition and Non-Solicitation Agreement (“Agreement”) effective on the last date signed below (the “Effective Date”), is between OvaScience, Inc. of Delaware (“OvaScience”) and Employee (“Employee”) (each referred to herein individually as a “Party,” and collectively as the “Parties”).

RECITALS.

WHEREAS, OvaScience wishes to protect against former employees using their knowledge of OvaScience, its business, and its proprietary information to the detriment of OvaScience through time-limited non-competition and non-solicitation provisions;

WHEREAS, OvaScience requires, as a condition of employment, that all employees sign a non-competition and non-solicitation agreement; and

WHEREAS, OvaScience has offered Employee a position with OvaScience, and Employee wishes to accept such offer.

NOW, THEREFORE, in consideration of the promises and other terms set forth below, the Parties agree as follows:

		
	I.
	Condition of Employment. Employee hereby agrees that his/her employment and/or the continuance of that employment with OvaScience is contingent upon his/her agreement to sign and adhere to the provisions of this Agreement.

		
	II.
	Non-Competition.  While Employee is employed with OvaScience and for a period of one (1) year after the termination or cessation of such employment for any reason (“No Conflict Period”), Employee shall not:

		
	A.
	directly or indirectly engage or assist others in engaging any business or enterprise (whether as owner, partner, officer, director, employee, consultant, investor, lender or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held company) that is competitive with OvaScience’s business, including any business or enterprise that develops, manufactures, markets, licenses, sells or provides any product or service that competes with any product or service that OvaScience either planned to or did develop, manufacture, market, license, sell or provide while Employee was employed by OvaScience; or

B.    either alone or in association with others, solicit, divert or take away, or attempt to solicit, divert or take away, the business or patronage of any of the clients, customers, or business partners of OvaScience which were contacted, solicited, or served by OvaScience during the 12-month period prior to the termination or cessation of Employee’s employment with OvaScience.
		
	III.
	Non-Solicitation.  During the No Conflict Period, Employee shall not either alone or in association with others: (1) solicit, induce, or attempt to induce, any employee or independent contractor of OvaScience to terminate their employment or other engagement with OvaScience; or (2) recruit, hire or attempt to hire, or engage or attempt to engage as an independent contractor, any person who was employed or otherwise engaged by OvaScience at any time during the term of Employee’s employment with OvaScience. Notwithstanding the foregoing, Employee may recruit, hire or attempt to hire, or engage or attempt to engage as an independent contractor, any individual whose employment or other engagement with OvaScience has been terminated for at least a six (6) month period.

		
	IV.
	Extension for Violations of Non-Competition or Non-Solicitation. If Employee violates any provision of Section II or III of this Agreement, Employee shall continue to be bound by the restrictions set forth in that Section until a period of one (1) year has expired without any violation of such provision.

V.    General Provisions.
A.    Remedies for Breach.  The provisions of this Agreement are necessary for the protection of the business and goodwill of the Parties, and are considered by the Parties to be reasonable for such purpose.  Employee acknowledges and agrees that any breach of this Agreement will cause substantial and irreparable injury to OvaScience; therefore, in the event of a breach and in addition to other remedies which may be available, OvaScience has the right to seek specific performance and other injunctive and equitable relief.
B.    Third Party Obligations. Employee acknowledges, represents, and warrants that this Agreement and Employee employment with OvaScience does not, and will not, violate any continuing obligation that has to any former employer or other third party.
C.    Disclosure of this Agreement.  Employee hereby authorizes OvaScience to notify others, including customers of OvaScience and any of Employee’s future employers or prospective business associates, of the terms and existence of this Agreement, and     Employee’s continuing obligations to OvaScience hereunder.
D.    Agreement Not an Employment Contract.  Employee acknowledges that this Agreement does not constitute a contract of employment, does not imply that OvaScience will continue his/her employment for any period of time, and does not change the at-will nature of his/her employment.

E.    Successors and Assigns.  This Agreement is binding upon, and inures to the benefit of, both Parties and their respective successors and assigns, including any corporation with which, or into which, OvaScience may be merged or which may succeed to its assets or business, provided, however, that the obligations of Employee are personal and therefore Employee may not assign them without Approval.  Employee hereby irrevocably consents to be bound by the provisions of this Agreement for the benefit of OvaScience and any subsidiary or affiliate thereof to whose employ Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.
F.    Severability.  If any provision of this Agreement is illegal or unenforceable, that provision is severed from this Agreement and all other provisions remain in force. If a court of competent jurisdiction deems any provision illegal or unenforceable, the Parties shall undertake to substitute a provision that is as commercially equivalent as possible, in light of the legal interests and intent of this Agreement.
G.    Waivers.  No delay or omission by OvaScience in exercising any right under this Agreement will operate as a waiver of that or any other right.  A waiver or consent given by OvaScience on any one occasion is effective only in that instance, and will not be construed as a bar to, or waiver of, any right on any other occasion.
H.    Choice of Law and Jurisdiction.  The validity, interpretation and performance of this Agreement is controlled by and construed under the laws of the Commonwealth of Massachusetts, without giving effect to the principles of conflicts of law thereof.  The Parties irrevocably submit to the exclusive jurisdiction of the federal and state courts located in Boston, MA.  Each Party hereby irrevocably waives any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding relating to this Agreement in Boston, MA and further irrevocably waives any claim that Boston, MA is not a convenient forum for any such suit, action or proceeding.  Additionally, each Party hereby irrevocably waives any right to a trial by jury in any action, suit or other proceeding arising under or relating to any provision of this Agreement.
I.        Entire Agreement.  This Agreement constitutes the entire agreement among the Parties and supersedes any prior or contemporaneous understanding or agreement with respect to the transaction contemplated hereby.
J.    Modification.  The Parties may only modify this Agreement by a writing signed by both Parties.  Any modifications not made in writing are not effective.
		
	K.  
	Counterparts.  For the convenience of the Parties, this Agreement can be executed by facsimile and in counterparts, each of which is deemed an original, and both of which taken together constitutes one agreement binding on both Parties.

L.    Construction.  All pronouns and variations thereof refer to masculine, feminine, or neuter genders, singular or plural, as the identity of the person may require. The words “include,” “including” and “includes” as used in this Agreement are deemed to be followed by the words “without limitation.”   This Agreement contains headings only for convenience and the headings do not constitute or form a part of this Agreement, and should not be used in the construction of this Agreement.

The Parties enter into this Agreement on the Effective Date.

OvaScience, Inc.                    Employee

___________________________________                                                                             
Signature                         Signature                     
______________________________________        ______________________________________
Print Name                        Print Name

______________________________________        ______________________________________
Title                            Title

______________________________________        ______________________________________
Date                            Date

74622414v.1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]